What's Changed!

Pre-Clinical:

New Developers join Pre-Clinical phases - "InstitutPasteur/ TheraVectys" & "United Biomedical (UBI)/ c19"

Clinical:

Sanofi / Regeneron; Feinstein Institutes; REMAP-CAP global trial is now discontinued.

Univ. of College, London joins Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial;

Phase I:

Oxford Expression Technologies joins Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma for vaccine trials Adimmune Corporation - Phase I began end of August 2020

Phase I / II:

Spy Biotech signs agreement with Serum Institute of India to develop COVID-19 vaccine based on research conducted in Australia 

Phase II:

Petrovax joins CanSino Biologics/Beijing Institute of Biotechnology Canada's National Research Council no more in partnership with CanSino Biologics/Beijing Institute of Biotechnology

COVID-19 Vaccine and Treatment Tracker

CoVaTrack is the first COVID-19 Vaccine & Treatment Tracker portal for India,
featuring the latest news and updates on vaccines & treatments for Novel Coronavirus, including clinical trials to approvals.

Global Statistics What's Changed!
  • 311

    Pre-clinical

    Treatments & Vaccines not yet in human trials

  • 205

    Clinical

    Treatments & vaccines undergoing clinical research

  • 14

    Phase I

    Clinical trials with volunteer groups of less than 100

  • 12

    Phase I / II

    Simultaneous trials on small & large patient groups

  • 3

    Phase II

    Clinical trials on larger groups of more than 100

  • 1

    Phase II / III

    Simultaneous trials in large and very large groups

  • 9

    Phase III

    Vaccines in large-scale efficacy tests

  • 0

    Approved

    Approved for nation-wide sale and usage

Last updated: 05:04 PM IST, 02th Dec 2020   |  
Source: Milken Institute & WHO

COVID-19 Vaccines Approved for Limited Use

NCT04437875
Phase III
Non-Replicating Viral Vector

Developer/Manufacturer :

Binnopharm

Researcher :

Gamaleya Research Institute

Vaccine/Treatment Type :

Non-Replicating Viral Vector

NCT04313127
Phase III
Non-Replicating Viral Vector

Developer/Manufacturer :

Cansino Biologics

Researcher :

Beijing Institute of Biotechnology / National Research Council (Canada)

Vaccine/Treatment Type :

Non-Replicating Viral Vector

NCT04352608
Phase III
Inactivated Virus

Developer/Manufacturer :

Sinovac Biotech / PT Bio Farma

Researcher :

Instituto Butantan

Vaccine/Treatment Type :

Inactivated Virus

COVID-19 Vaccine & Treatment Statistics

Covid-19 Vaccine Trial Status
Status Trial
Confirmed 3079
Confirmed Or Healthy 31
Confirmed Or Suspected 198
Confirmed, Suspected Or Healthy 7
Healthy 436
NA 613
Resolved 32
Resolved Or Healthy 1
Suspected 37
Suspected Or Healthy 3
Unclear 10
Final 4447
Phase Wise % and No. of Developers
Stage Development % Frequency
Regulatory Review 0.02 2
Pre-clinical 54.18 6836
Clinical 38.99 4920
Phase I 2.19 276
Phase I/II 2.35 297
Phase II 0.57 72
Phase II/III 0.17 22
Phase III 1.53 193
Trial Stages
Stage Trial
Regulatory Review 2
Pre-clinical 6836
Clinical 4920
Phase I 276
Phase I/II 297
Phase II 72
Phase II/III 22
Phase III 193
Final 12618
Product Category Wise Treatments
Treatments & Vaccines Treatments
Antibodies 80
Antivirals 32
Cell-Based Therapy 35
Device 10
DNA - Based 20
Inactivated Virus 18
Live Attenuated Virus 4
Non-Replicating Viral Vector 28
Protein Subunit 77
Replicating Bacterial Vector 2
Replicating viral vector 20
RNA- Based Treatments 6
RNA- Based Vaccine 29
Scanning Compounds to Repurpose 21
Virus Like Particle 20
Others 154
Final 556
Treatment Trials Active or Dormant
Healthy Confirmed Healthy or Suspected Suspected or Unclear Final
1000 569 231 1800
1000 569 231 1800
1000 569 231 1800
1000 569 231 1800
1000 569 231 1800
1000 569 231 1800
1000 569 231 1800
1000 569 231 1800
1000 569 231 1800

COVID-19 Vaccines & Treatments (India)

Over 30 organizations are trying to develop a vaccine to fight COVID-19.
World Health Organization (WHO) has already approved seven vaccine candidates for India.

Pre-clinical

3

Clinical

0

Phase I

2

Phase II

1

Phase III

1

Approved

0

Vaccine Tracker

  • Developer

    Bharat Biotech International Limited

  • Researcher

    ICMR - National Institute of Virology, Pune

  • Vaccine Candidate

    CTRI/2020/07/026300

  • Phase

    Phase II / Phase I

  • Developer

    Cadila Healthcare Ltd.

  • Researcher

    Cadila Healthcare Ltd.

  • Vaccine Candidate

    CTRI/2020/07/026352

  • Phase

    Phase II / Phase I

  • Developer

    Cadila Pharmaceuticals Ltd.

  • Researcher

    CSIR

  • Vaccine Candidate

    CTRI/2020/04/024846

  • Phase

    Phase III

  • Developer

    Green Signal Biopharma Ltd.

  • Researcher

    JIPMER

  • Vaccine Candidate

    CTRI/2020/04/024833

  • Phase

    N/A

  • Developer

    Haffkine Institute for Training Research & Testing

  • Researcher

    Haffkine Institute for Training Research & Testing

  • Vaccine Candidate

    CTRI/2020/05/025013

  • Phase

    Phase II

  • Developer

    Indian Immunologicals Limited

  • Researcher

    Griffith University, Australia

  • Vaccine Candidate

    Pre-Clinical

  • Phase

    N/A

  • Developer

    Mynvax

  • Researcher

    Indian Institute of Science (Bengaluru)

  • Vaccine Candidate

    Pre-Clinical

  • Phase

    N/A

  • Developer

    Panacea Biotec Limited

  • Researcher

    Refana Inc, US

  • Vaccine Candidate

    Pre-Clinical

  • Phase

    N/A

  • Developer

    Serum Institute of India

  • Researcher

    National Institute for Research in Tuberculosis

  • Vaccine Candidate

    CTRI/2020/06/025854

  • Phase

    N/A

  • Developer

    Serum institute of India & AstraZeneca

  • Researcher

    University of Oxford

  • Vaccine Candidate

    CTRI/2020/04/024749

  • Phase

    Phase III

Developer Researcher Vaccine Candidate Phase
Bharat Biotech International Limited ICMR - National Institute of Virology, Pune CTRI/2020/07/026300 Phase II / Phase I
Cadila Healthcare Ltd. Cadila Healthcare Ltd. CTRI/2020/07/026352 Phase II / Phase I
Cadila Pharmaceuticals Ltd. CSIR CTRI/2020/04/024846 Phase III
Green Signal Biopharma Ltd. JIPMER CTRI/2020/04/024833 N/A
Haffkine Institute for Training Research & Testing Haffkine Institute for Training Research & Testing CTRI/2020/05/025013 Phase II
Indian Immunologicals Limited Griffith University, Australia Pre-Clinical N/A
Mynvax Indian Institute of Science (Bengaluru) Pre-Clinical N/A
Panacea Biotec Limited Refana Inc, US Pre-Clinical N/A
Serum Institute of India National Institute for Research in Tuberculosis CTRI/2020/06/025854 N/A
Serum institute of India & AstraZeneca University of Oxford CTRI/2020/04/024749 Phase III

Treatment Tracker

Abu Dhabi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Abu Dhabi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    45000

Abu Dhabi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any)

  • Treatment

    SOC, Stem cells

  • Trial Participants

    146

Abu Dhabi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Serious Adverse Events

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    80

Accra
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, Pneumonia or ARDS, Distress

  • Treatment

    HCQ, HCQ + LPV/r, LPV/r, SOC

  • Trial Participants

    6400

Accra
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    3000

Accra
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    6400

Accra
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Mortality, Hospital Discharge, Pneumonia or ARDS, Distress

  • Treatment

    HCQ, HCQ + LPV/r, LPV/r, SOC

  • Trial Participants

    6400

Adana
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Addis Ababa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    3000

Aguascalientes
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + Ivermectin, Ivermectin

  • Trial Participants

    108

Aichi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Aichi
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    FPV + Corticosteroids

  • Trial Participants

    69

Aichi
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    FPV, SOC

  • Trial Participants

    86

Al Iskandariyah
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Imatinib, SOC

  • Trial Participants

    30

Al Madinah
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    FPV, SOC

  • Trial Participants

    576

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    DHODH inhibitor, SOC

  • Trial Participants

    100

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Alabama
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    436

Alabama
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    45

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir

  • Trial Participants

    1500

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1344

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6

  • Treatment

    Other, SOC

  • Trial Participants

    100

Alabama
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization

  • Treatment

    Inhaled solution + Other, SOC

  • Trial Participants

    44

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    300

Alabama
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Anti SARS-COV-2 Titers, Antibodies

  • Treatment

    HCQ, SOC

  • Trial Participants

    58

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    61

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    702

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    150

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Treatment-emergent Adverse Events

  • Treatment

    NA

  • Trial Participants

    100

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    NA

  • Trial Participants

    60

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    200

Alabama
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    208

Alagoas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

Alagoas
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    HCQ, SOC

  • Trial Participants

    1300

Alava
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Alava
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Albacete
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Albacete
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Alberta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    148

Alberta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization

  • Treatment

    HCQ, SOC

  • Trial Participants

    70

Alberta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1200

Alberta
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality

  • Treatment

    TCZ

  • Trial Participants

    30

Alberta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    LPV/r, SOC

  • Trial Participants

    2900

Alberta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    100

Alberta
  • COVID-19 status

    Confirmed, Suspected Or Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH

  • Treatment

    HCQ, SOC

  • Trial Participants

    1309

Alberta
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count

  • Treatment

    Vitamins

  • Trial Participants

    64

Alberta
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    ARBs, SOC

  • Trial Participants

    1372

Alberta
  • COVID-19 status

    Suspected

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, SpO2

  • Treatment

    Positioning, SOC

  • Trial Participants

    596

Alborz
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Anti SARS-COV-2 Titers

  • Treatment

    SOC, Vaccine

  • Trial Participants

    500

Alborz
  • COVID-19 status

    Confirmed

  • Outcome

    Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Alternative therapy

  • Trial Participants

    48

Alessandria
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings

  • Treatment

    TCZ

  • Trial Participants

    400

Alicante
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Adverse Events

  • Treatment

    Nutrition, SOC

  • Trial Participants

    40

Alicante
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Alicante
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Amazonas
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, Natural Killer Cell Count

  • Treatment

    NA

  • Trial Participants

    152

Amazonas
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    416

Amazonas
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Amman
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings

  • Treatment

    Stem cells

  • Trial Participants

    5

Amman
  • COVID-19 status

    Healthy

  • Outcome

    IL-1, IL-6, Tumor Necrosis Factor (Any)

  • Treatment

    Vitamins

  • Trial Participants

    100

Amman
  • COVID-19 status

    Healthy

  • Outcome

    IL-1, IL-6, Tumor Necrosis Factor (Any)

  • Treatment

    Nutrition, SOC

  • Trial Participants

    100

Amman
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Adverse Events

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    200

Amman
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, HCQ + Other

  • Trial Participants

    58

Amman
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    45000

Amsterdam
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-2, IL-6, IL-8, LDH, Radiographic Findings

  • Treatment

    TCZ

  • Trial Participants

    NA

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge

  • Treatment

    Other, SOC

  • Trial Participants

    120

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life

  • Treatment

    SOC, TCZ

  • Trial Participants

    450

Amsterdam
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    ARBs, SOC

  • Trial Participants

    641

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    426

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission

  • Treatment

    Plasma-based therapy

  • Trial Participants

    690

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Amsterdam
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Fever, Adverse Events, C-Reactive Protein, Respiratory Rate

  • Treatment

    HCQ, HCQ + AZT

  • Trial Participants

    60

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1500

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ

  • Trial Participants

    12

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events

  • Treatment

    Vaccine

  • Trial Participants

    10078

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    mAB, SOC

  • Trial Participants

    80

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    300

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    Monocyte Count

  • Treatment

    Vaccine + Bisphosphonate, Vaccine + Vaccine

  • Trial Participants

    NA

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, PaO2-FiO2

  • Treatment

    IFN, SOC

  • Trial Participants

    390

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation

  • Treatment

    ARBs, SOC

  • Trial Participants

    651

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Amsterdam
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, PaO2-FiO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Anesthetic

  • Trial Participants

    20

Amsterdam
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Dyspnea, Adverse Events, Heart Rate, PaO2-FiO2, Quality of Life

  • Treatment

    Device, SOC

  • Trial Participants

    13

Amsterdam
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Renal Outcome (Unspecified)

  • Treatment

    Other, SOC

  • Trial Participants

    124

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    Monocyte Count

  • Treatment

    SOC, Vaccine, Vaccine + Bisphosphonate, Vaccine + Vaccine

  • Trial Participants

    100

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1600

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    430

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    NA

  • Trial Participants

    950

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Positioning, SOC

  • Trial Participants

    342

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Albumin, PaO2-FiO2

  • Treatment

    NA

  • Trial Participants

    386

Amsterdam
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, IL-8, Radiographic Findings

  • Treatment

    TCZ

  • Trial Participants

    354

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2

  • Treatment

    HCQ, SOC

  • Trial Participants

    8

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    mAb

  • Trial Participants

    80

Amsterdam
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS

  • Treatment

    SOC, Vaccine

  • Trial Participants

    NA

Amsterdam
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, PaO2-FiO2

  • Treatment

    NA

  • Trial Participants

    386

Ancona
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, HCQ + JAKi

  • Trial Participants

    116

Andhra Pradesh
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Nutrition, SOC

  • Trial Participants

    124

Anhui
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Lung Inflamation

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Anhui
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    60

Anhui
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    FPV, SOC

  • Trial Participants

    210

Anhui
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    750

Anhui
  • COVID-19 status

    Confirmed

  • Outcome

    Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    200

Anhui
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    SOC, TCZ

  • Trial Participants

    188

Ankara
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Procalcitonin, Fibrinogen

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    60

Ankara
  • COVID-19 status

    Unclear

  • Outcome

    Organ Failure or Dysfunction (SOFA), PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    60

Ankara
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Ankara
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Other, SOC

  • Trial Participants

    200

Ankara
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Ankara
  • COVID-19 status

    Resolved

  • Outcome

    6-Minute Walking Distance

  • Treatment

    Exercise, Rehabilitation

  • Trial Participants

    122

Ankara
  • COVID-19 status

    NA

  • Outcome

    Serious Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    43998

Ankara
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Monitoring, SOC

  • Trial Participants

    100

Ankara
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    140

Ankara
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospital Discharge, Viral Load or Clearance

  • Treatment

    FPV, FPV + AZT, HCQ, HCQ + AZT, HCQ + FPV

  • Trial Participants

    1000

Ankara
  • COVID-19 status

    Confirmed

  • Outcome

    Dyspnea, Other Mild Symptoms

  • Treatment

    Other, SOC

  • Trial Participants

    34

Ankara
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + Zinc + Vitamins + AZT

  • Trial Participants

    200

Ankara
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    177

Ankara
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Antalya
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Other, SOC

  • Trial Participants

    200

Antananarivo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, Other + Vitamins, SOC

  • Trial Participants

    60

Antioquia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Igs, Plasma based therapy, SOC

  • Trial Participants

    75

Antwerp
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    260

Antwerp
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Radiographic Findings, Hypoxia

  • Treatment

    Anakinra, Anakinra + Siltuximab, Anakinra + TCZ, Siltuximab, SOC, TCZ

  • Trial Participants

    342

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    479

Arizona
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1230

Arizona
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    4000

Arizona
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

Arizona
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    Natural Killer Cells, SOC

  • Trial Participants

    86

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH

  • Treatment

    Remdesivir, Remdesivir + mAb

  • Trial Participants

    200

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH

  • Treatment

    Colchicine, SOC

  • Trial Participants

    6000

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Hormone therapy, SOC

  • Trial Participants

    198

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1344

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + mAb

  • Trial Participants

    200

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    264

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    52

Arizona
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance

  • Treatment

    FPV, SOC

  • Trial Participants

    50

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Other, SOC

  • Trial Participants

    40

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    702

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    500

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2

  • Treatment

    Merimepodib + Remdesivir, Remdesivir

  • Trial Participants

    80

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Fever

  • Treatment

    Other, SOC

  • Trial Participants

    40

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    500

Arizona
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate

  • Treatment

    AZT + Antibiotics

  • Trial Participants

    25

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any)

  • Treatment

    mAb, SOC

  • Trial Participants

    186

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    30

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Arizona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    mAb, SOC

  • Trial Participants

    300

Arkansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Arkansas
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Arkansas
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    Natural Killer Cells, SOC

  • Trial Participants

    86

Arkansas
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Deep Vein Thrombosis or Pulmonary Embolism, Renal Outcome (Unspecified)

  • Treatment

    Other

  • Trial Participants

    366

Arkansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Hormone therapy, SOC

  • Trial Participants

    198

Arkansas
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    Plasma based therapy

  • Trial Participants

    NA

Arkansas
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Serious Adverse Events

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    600

Arkansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Astana
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    244

Astana
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy

  • Trial Participants

    200

Asturias
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Asturias
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Asturias
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Asturias
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress

  • Treatment

    Other, SOC

  • Trial Participants

    100

Asturias
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Asturias
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    208

Asturias
  • COVID-19 status

    NA

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    278

Asyut
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Adverse Events, IgG, IgM or IgA

  • Treatment

    Igs

  • Trial Participants

    100

Athens
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    900

Athens
  • COVID-19 status

    NA

  • Outcome

    Other Mild Symptoms, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Anakinra + Cotrimoxazole

  • Trial Participants

    400

Athens
  • COVID-19 status

    NA

  • Outcome

    Dyspnea, Other Mild Symptoms, Quality of Life, Depression, Anxiety

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    100

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), PaO2-FiO2, Radiographic Findings

  • Treatment

    Anakinra, TCZ

  • Trial Participants

    40

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Plasma based therapy

  • Trial Participants

    60

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Monocyte Count

  • Treatment

    Antibiotics

  • Trial Participants

    90

Athens
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Cough, Dyspnea

  • Treatment

    Antibiotics

  • Trial Participants

    90

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Non-invasive Ventilation

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    400

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Hormone therapy, SOC

  • Trial Participants

    60

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Fibrinogen, ALT, Bilirubin, Urine Sample, Blood Pressure, PaO2-FiO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Hormone therapy, SOC

  • Trial Participants

    60

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Anakinra, TCZ

  • Trial Participants

    40

Athens
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Athens
  • COVID-19 status

    Healthy

  • Outcome

    IgG, IgM or IgA, Radiographic Findings, Cardiac Outcome (Unspecified)

  • Treatment

    SOC, Vaccine

  • Trial Participants

    900

Athens
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    NA

  • Trial Participants

    60

Atlantico
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Aude
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-2, PaO2-FiO2, Patient Positioning

  • Treatment

    Other, SOC

  • Trial Participants

    30

Badajoz
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Baden-Wurttemberg
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2

  • Treatment

    SOC, TCZ

  • Trial Participants

    200

Baden-Wurttemberg
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, D-Dimer, Urine Sample

  • Treatment

    ECMO, ECMO + Cytokine removal

  • Trial Participants

    80

Baden-Wurttemberg
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, IL-6

  • Treatment

    ECMO, ECMO + Cytokine removal

  • Trial Participants

    30

Baghdad
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    HCQ + AZT, HCQ + Plasma based therapy + AZT

  • Trial Participants

    49

Baghdad
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    HCQ + AZT, HCQ + AZT + Other

  • Trial Participants

    16

Baghdad
  • COVID-19 status

    NA

  • Outcome

    Mortality

  • Treatment

    Ivermectin + Antibiotics, SOC

  • Trial Participants

    140

Bahia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

Bahia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Bahia
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    5000

Bahia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, D-Dimer, Troponin

  • Treatment

    Anticoagulants

  • Trial Participants

    600

Bahia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Dexamethasone, SOC

  • Trial Participants

    299

Bahia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    HCQ, SOC

  • Trial Participants

    1300

Baleares
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Bangui
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, IgG, IgM or IgA, Antibodies, SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Igs, SOC

  • Trial Participants

    10

Barcelona
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, ECG

  • Treatment

    Antivirals, SOC

  • Trial Participants

    200

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    116

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Anticoagulants

  • Trial Participants

    164

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG

  • Treatment

    Other

  • Trial Participants

    46

Barcelona
  • COVID-19 status

    NA

  • Outcome

    Mortality, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1300

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings

  • Treatment

    HCQ + Antivirals, SOC

  • Trial Participants

    2300

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    420

Barcelona
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Igs

  • Trial Participants

    100

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress

  • Treatment

    Other, SOC

  • Trial Participants

    100

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Anakinra, SOC

  • Trial Participants

    180

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Adverse Events

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    72

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    102

Barcelona
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events

  • Treatment

    Vaccine

  • Trial Participants

    10078

Barcelona
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, LDH, Cardiac Outcome (Unspecified)

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    300

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Positioning + Respiratory support, Respiratory support

  • Trial Participants

    248

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Barcelona
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Cytokine removal, SOC

  • Trial Participants

    40

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, Coagulation Test, ALT, AST, Albumin, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    SOC, TCZ + mAb

  • Trial Participants

    24

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    380

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Hypoxemia

  • Treatment

    Corticosteroids, Siltuximab

  • Trial Participants

    200

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Treatment-emergent Adverse Events, ECG

  • Treatment

    SOC, Trimodulin

  • Trial Participants

    164

Barcelona
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    440

Barcelona
  • COVID-19 status

    Resolved

  • Outcome

    Quality of Life, Depression, Anxiety

  • Treatment

    Rehabilitation, SOC

  • Trial Participants

    102

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Barcelona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, TCZ + AZT + HCQ

  • Trial Participants

    276

Barcelona
  • COVID-19 status

    Resolved

  • Outcome

    NA

  • Treatment

    Corticosteroids

  • Trial Participants

    120

Barnet
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Barnsley
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    150

Basel-Stadt
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    mAb

  • Trial Participants

    NA

Bayern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Bayern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    400

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), C-Reactive Protein, Ferritin, IL-6, Interferon (Any), Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, ALT, Albumin, Bilirubin, IgG, IgM or IgA, Blood Gas, ECG, SpO2, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    SOC, Stem cells

  • Trial Participants

    200

Beijing
  • COVID-19 status

    NA

  • Outcome

    PaO2-FiO2

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    200

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Other Mild Symptoms, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Natural Killer Cell Count, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    20

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Neutrophils, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, CK-MB, LDH, Antibodies, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    50

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings

  • Treatment

    FPV, HCQ + FPV, SOC

  • Trial Participants

    150

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings

  • Treatment

    HCQ, SOC

  • Trial Participants

    300

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events

  • Treatment

    Igs, SOC

  • Trial Participants

    80

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    422

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Procalcitonin, Radiographic Findings

  • Treatment

    mAb, Other

  • Trial Participants

    120

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Fever, C-Reactive Protein, D-Dimer, PaO2-FiO2, Respiratory Rate, Radiographic Findings

  • Treatment

    mAb

  • Trial Participants

    20

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events

  • Treatment

    LPV/r + IFN, SOC

  • Trial Participants

    90

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings

  • Treatment

    Umifenovir, Umifenovir + IFN

  • Trial Participants

    100

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings

  • Treatment

    LPV/r, Oseltamivir, SOC, Umifenovir

  • Trial Participants

    400

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, C-Reactive Protein, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, ALT, PaO2-FiO2, Respiratory Rate

  • Treatment

    Oseltamivir, Oseltamivir + Antivirals, Other + Oseltamivir

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Radiographic Findings

  • Treatment

    Corticosteroids

  • Trial Participants

    100

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Antibodies, PaO2-FiO2, Radiographic Findings

  • Treatment

    Igs

  • Trial Participants

    10

Beijing
  • COVID-19 status

    Resolved

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Cough, Dyspnea

  • Treatment

    FPV, FPV + HCQ, SOC

  • Trial Participants

    150

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    mAb, SOC

  • Trial Participants

    140

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, CK-MB, Procalcitonin

  • Treatment

    NA

  • Trial Participants

    9

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events

  • Treatment

    DAA + IFN

  • Trial Participants

    11

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Visits or Returns to Emergency Department

  • Treatment

    Antimalarial, SOC

  • Trial Participants

    275

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, PaO2-FiO2, Respiratory Rate

  • Treatment

    SOC, TCM

  • Trial Participants

    550

Beijing
  • COVID-19 status

    Resolved

  • Outcome

    Pneumonia or ARDS, Dyspnea, 6-Minute Walking Distance, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    160

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, 3CL Mpro, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Dendritic Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, ALT, Urine Sample, Stool Sample, Radiographic Findings

  • Treatment

    LPV/r + IFN, LPV/r + IFN + TCM

  • Trial Participants

    20

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Radiographic Findings

  • Treatment

    FPV, FPV + TCZ, TCZ

  • Trial Participants

    150

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events

  • Treatment

    Other

  • Trial Participants

    25

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    308

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    237

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    PaO2-FiO2, Radiographic Findings, Hypoxia, Hypoxemia

  • Treatment

    Stem cells

  • Trial Participants

    24

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    50

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), PaO2-FiO2, Respiratory Rate, Hypoxia, Hypoxemia

  • Treatment

    SOC, Vitamins

  • Trial Participants

    56

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Cough, Fever, Dyspnea

  • Treatment

    SOC, TCM

  • Trial Participants

    120

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    200

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    471

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    86

Beijing
  • COVID-19 status

    NA

  • Outcome

    PaO2-FiO2

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    20

Beijing
  • COVID-19 status

    NA

  • Outcome

    Serious Adverse Events, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    600

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Radiographic Findings

  • Treatment

    DAA, SOC

  • Trial Participants

    342

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Stool Sample

  • Treatment

    Alternative therapy

  • Trial Participants

    76

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Cough, Fever, Dyspnea

  • Treatment

    LPV/r, LPV/r + TCM

  • Trial Participants

    80

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)

  • Treatment

    Other

  • Trial Participants

    19

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)

  • Treatment

    Cytokine removal

  • Trial Participants

    19

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events, Radiographic Findings

  • Treatment

    mAb, SOC

  • Trial Participants

    12

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events, Radiographic Findings

  • Treatment

    mAb, SOC

  • Trial Participants

    12

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Psychological therapy

  • Trial Participants

    1600

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IgG, IgM or IgA

  • Treatment

    HCQ

  • Trial Participants

    100

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Pneumonia or ARDS, Cough, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings

  • Treatment

    IFN, SOC

  • Trial Participants

    450

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IgG, IgM or IgA

  • Treatment

    HCQ

  • Trial Participants

    100

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Radiographic Findings

  • Treatment

    Carrimycin, HCQ or LPV/r or Umifenovir

  • Trial Participants

    520

Beijing
  • COVID-19 status

    NA

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    744

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance

  • Treatment

    SOC, TCM

  • Trial Participants

    204

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    TCM

  • Trial Participants

    300

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, PaO2-FiO2

  • Treatment

    TCM

  • Trial Participants

    116

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Serious or Seconday Infections, Lymphocyte Count, IgG, IgM or IgA, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings

  • Treatment

    HCQ, SOC

  • Trial Participants

    78

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Radiographic Findings

  • Treatment

    LPV/r + IFN + TCM + Non-invasive respiratory support, LPV/r + Non-invasive respiratory support + IFN

  • Trial Participants

    150

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Fever, C-Reactive Protein, Ferritin, Radiographic Findings, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    300

Beijing
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    SOC, Stem cells

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    40

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever

  • Treatment

    LPV/r + IFN, TCM

  • Trial Participants

    348

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    30

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, MIP-1

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    40

Beijing
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    SOC, TCM

  • Trial Participants

    300

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms

  • Treatment

    FPV

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    TCM

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Radiographic Findings, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Cough, Fever, Dyspnea, Respiratory Rate, Radiographic Findings

  • Treatment

    IFN, SOC

  • Trial Participants

    300

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, Stem cells

  • Trial Participants

    120

Beijing
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events

  • Treatment

    NA

  • Trial Participants

    10

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Non-invasive Ventilation, Cough, Other Mild Symptoms, Adverse Events, Radiographic Findings

  • Treatment

    Antivirals, SOC

  • Trial Participants

    342

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Pneumonia or ARDS, Non-invasive Ventilation, Cough, Fever

  • Treatment

    FPV, SOC

  • Trial Participants

    256

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever

  • Treatment

    Carrimycin, LPV/r

  • Trial Participants

    520

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    942

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Fever, Radiographic Findings, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    408

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever

  • Treatment

    SOC, TCM

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, Pneumonia or ARDS, Serious Adverse Events, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    15000

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein, IL-6, PaO2-FiO2, Radiographic Findings

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    45

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Creatinine Phosphokinase, ALT, CD4, CD8

  • Treatment

    SOC, Stem cells

  • Trial Participants

    20

Beijing
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Fever, Other Mild Symptoms

  • Treatment

    SOC, TCM

  • Trial Participants

    2000

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, White Blood Cell Count, Monocyte Count, Hemoglobin, Erythrocyte Sedimentation Rate, Radiographic Findings

  • Treatment

    LPV/r, LPV/r + TCM, TCM

  • Trial Participants

    60

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, PaO2-FiO2, Respiratory Rate

  • Treatment

    SOC, TCM

  • Trial Participants

    42

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate

  • Treatment

    SOC, TCM

  • Trial Participants

    120

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events, Antibodies

  • Treatment

    mAb, SOC

  • Trial Participants

    33

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Radiographic Findings

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    80

Beijing
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    NA

  • Trial Participants

    10

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, PaO2-FiO2, Respiratory Rate

  • Treatment

    LPV/r, Other

  • Trial Participants

    160

Beijing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    FPV, FPV + TCZ, TCZ

  • Trial Participants

    150

Beijing
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    40

Beirut
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Belfast
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Bergamo
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Bergamo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Bergamo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Non-invasive Ventilation

  • Treatment

    Plasma based therapy

  • Trial Participants

    10

Bergamo
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    IL-1, IL-2, IL-6, IL-7, IL-10, Tumor Necrosis Factor (Any), MCP-1, IgG, IgM or IgA, Antibodies, Radiographic Findings

  • Treatment

    Igs

  • Trial Participants

    10

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    ECMO

  • Trial Participants

    200

Berlin
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    NA

  • Trial Participants

    17

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Renal Outcome (Unspecified)

  • Treatment

    Cytokine removal, SOC

  • Trial Participants

    100

Berlin
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    200

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, SpO2, Respiratory Rate

  • Treatment

    DAA, HCQ, SOC

  • Trial Participants

    90

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Hygiene

  • Trial Participants

    50

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Anticoagulants

  • Trial Participants

    172

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    440

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    NA

  • Trial Participants

    350

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Visits or Returns to Emergency Department

  • Treatment

    Device + Other, SOC

  • Trial Participants

    600

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    230

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Treatment-emergent Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    2500

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    120

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), C-Reactive Protein, Troponin

  • Treatment

    NA

  • Trial Participants

    334

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life

  • Treatment

    SOC, TCZ

  • Trial Participants

    450

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), D-Dimer, Weight, Height or BMI, Troponin, Procalcitonin, LDH, IgG, IgM or IgA, Antibodies, Blood Pressure, Heart Rate, ECG, SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    230

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Hyper-Inflammation, Radiographic Findings

  • Treatment

    JAKi

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Unclear

  • Outcome

    Adverse Events

  • Treatment

    Device

  • Trial Participants

    20

Berlin
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    59

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Monocyte Count, Neutrophils, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, ECG

  • Treatment

    Other, SOC

  • Trial Participants

    183

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    420

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Lymphocyte Count, D-Dimer, Antibodies

  • Treatment

    SOC, Stem cells

  • Trial Participants

    40

Berlin
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Ferritin, IL-6, D-Dimer, Procalcitonin, Shock, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    SOC, TCZ

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Berlin
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    106

Berlin
  • COVID-19 status

    NA

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    220

Berlin
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, Radiographic Findings

  • Treatment

    JAKi

  • Trial Participants

    15

Berlin
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Fever

  • Treatment

    SOC, Vaccine

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    NA

  • Outcome

    Serious Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    43998

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    140

Berlin
  • COVID-19 status

    Healthy

  • Outcome

    Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    120

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization

  • Treatment

    HCQ, SOC

  • Trial Participants

    350

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, Weight, Height or BMI, Coagulation Test, LDH, Blood Pressure, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    300

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, C-Reactive Protein, Ferritin, IL-6, IgG, IgM or IgA

  • Treatment

    JAKi

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Fever

  • Treatment

    SOC, Vaccine

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Antibodies

  • Treatment

    JAKi

  • Trial Participants

    200

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Pneumonia or ARDS, Non-invasive Ventilation, Cough, Fever

  • Treatment

    FPV, SOC

  • Trial Participants

    256

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    ARBs, SOC

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    284

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, LDH

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    200

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    177

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, D-Dimer, Urine Sample

  • Treatment

    ECMO, ECMO + Cytokine removal

  • Trial Participants

    80

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    400

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, PaO2-FiO2

  • Treatment

    IFN, SOC

  • Trial Participants

    390

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, PaO2-FiO2

  • Treatment

    SOC, Stem cells

  • Trial Participants

    64

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    220

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)

  • Treatment

    IFN, LPV/r, Remdesivir, SOC

  • Trial Participants

    NA

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    460

Berlin
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2

  • Treatment

    mAb, SOC

  • Trial Participants

    270

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    90

Bern
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test

  • Treatment

    Anticoagulants

  • Trial Participants

    200

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Treatment-emergent Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    2500

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Lymphocyte Count, Procalcitonin

  • Treatment

    Inhaled solution

  • Trial Participants

    80

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization

  • Treatment

    Vitamins

  • Trial Participants

    80

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Nutrition

  • Trial Participants

    240

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism

  • Treatment

    SOC, TCZ

  • Trial Participants

    5

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, C-Reactive Protein, Ferritin, White Blood Cell Count, PaO2-FiO2

  • Treatment

    Radiation therapy

  • Trial Participants

    22

Bern
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, MCP-1, Procalcitonin, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Anesthetic, SOC

  • Trial Participants

    64

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Hemoglobin, D-Dimer, eGFR, Glucose, Renal Outcome (Unspecified)

  • Treatment

    mAb, SOC

  • Trial Participants

    116

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Non-invasive Ventilation, PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    120

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Coagulation Test

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    1000

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Bern
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r

  • Trial Participants

    300

Bern
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Serious Adverse Events

  • Treatment

    Plasma based therapy

  • Trial Participants

    15

Bio-Bio
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    524

Birmingham
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Pneumonia or ARDS

  • Treatment

    AZT, SOC

  • Trial Participants

    800

Birmingham
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

Bissau
  • COVID-19 status

    Healthy

  • Outcome

    Mortality

  • Treatment

    SOC, Vaccine

  • Trial Participants

    3400

Bissau
  • COVID-19 status

    Unclear

  • Outcome

    Mortality

  • Treatment

    Device, SOC

  • Trial Participants

    66000

Bizkaia
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Bizkaia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Bizkaia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Bizkaia
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events

  • Treatment

    Vaccine

  • Trial Participants

    10078

Bogota
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Treatment-emergent Adverse Events

  • Treatment

    HCQ + LPV/r, HCQ + LPV/r + Alternative therapy

  • Trial Participants

    100

Bogota
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    AZT, HCQ, LPV/r, SOC

  • Trial Participants

    1200

Bogota
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    HCQ + LPV/r or AZT, Stem cells

  • Trial Participants

    40

Bogota
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events, Treatment-emergent Adverse Events

  • Treatment

    NA

  • Trial Participants

    10

Bogota
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    400

Bogota
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    86

Bogota
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Bogota
  • COVID-19 status

    NA

  • Outcome

    Mortality, Viral Load or Clearance, Adverse Events, Serious Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1000

Bogota
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events

  • Treatment

    NRTIs, SOC

  • Trial Participants

    950

Bogota
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Bogota
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    231

Bogota
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    60000

Bogota
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    60

Bogota
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Hypoxemia

  • Treatment

    Other, SOC

  • Trial Participants

    284

Bolivar
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Bologna
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    102

Bologna
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Anticoagulants

  • Trial Participants

    300

Bologna
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Bradford
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Bradford
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    150

Brandenburg
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    400

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Radiographic Findings, Depression, Anxiety

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    100

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    64

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Adverse Events, C-Reactive Protein, Renal Outcome (Unspecified)

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    120

Brasilia
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    ARBs + ACEi, SOC

  • Trial Participants

    700

Brasilia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life

  • Treatment

    HCQ, HCQ + AZT

  • Trial Participants

    440

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Antisense therapy, SOC

  • Trial Participants

    110

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    SOC, TCZ

  • Trial Participants

    60

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    420

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    HCQ + AZT

  • Trial Participants

    400

Brasilia
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Brasilia
  • COVID-19 status

    Unclear

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any)

  • Treatment

    HCQ + AZT

  • Trial Participants

    200

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin

  • Treatment

    mAb, SOC

  • Trial Participants

    270

Brasilia
  • COVID-19 status

    NA

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    SOC, TCZ

  • Trial Participants

    379

Brasilia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    NA

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    90

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Antivirals, SOC

  • Trial Participants

    584

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    mAb, Other, SOC

  • Trial Participants

    390

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Lymphocyte Count, D-Dimer

  • Treatment

    Other, SOC

  • Trial Participants

    68

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Hormone therapy + Ivermectin + AZT, Ivermectin + AZT

  • Trial Participants

    381

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    52

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    300

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission

  • Treatment

    Antihypertensive

  • Trial Participants

    240

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2

  • Treatment

    NA

  • Trial Participants

    120

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Platelet Count, Prothrombin, Fibrinogen

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    462

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    100

Brasilia
  • COVID-19 status

    NA

  • Outcome

    Serious Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    43998

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    140

Brasilia
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1000

Brasilia
  • COVID-19 status

    Healthy

  • Outcome

    Treatment-emergent Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    200

Brasilia
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Respiratory Rate, Hypoxia

  • Treatment

    Other

  • Trial Participants

    42

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge

  • Treatment

    Device, SOC

  • Trial Participants

    30

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    100

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Non-invasive Ventilation, Fever, SpO2, Respiratory Rate

  • Treatment

    Remdesivir, Remdesivir + TCZ

  • Trial Participants

    500

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Brasilia
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    2000

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    150

Brasilia
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    5000

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    410

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    3000

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    Other, SOC

  • Trial Participants

    100

Brasilia
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    60000

Brasilia
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13060

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any)

  • Treatment

    mAb, SOC

  • Trial Participants

    573

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, TCZ

  • Trial Participants

    129

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    177

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), C-Reactive Protein

  • Treatment

    Acalabrutinib

  • Trial Participants

    48

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    380

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, D-Dimer, Troponin

  • Treatment

    Anticoagulants

  • Trial Participants

    600

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Stem cells

  • Trial Participants

    90

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Antivirals, SOC

  • Trial Participants

    50

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Brasilia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Dexamethasone, SOC

  • Trial Participants

    299

Brasilia
  • COVID-19 status

    Healthy

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Adverse Events, Heart Rate, ECG

  • Treatment

    HCQ, SOC

  • Trial Participants

    400

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Other, SOC

  • Trial Participants

    310

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Brasilia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2

  • Treatment

    HCQ, SOC

  • Trial Participants

    630

Brasilia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    HCQ, SOC

  • Trial Participants

    1300

Brasilia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    465

Brescia
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Brescia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Brescia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Anticoagulants

  • Trial Participants

    300

Brescia
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Adverse Events, Radiographic Findings

  • Treatment

    Radiation therapy

  • Trial Participants

    30

Bristol
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1090

Bristol
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    150

British Columbia
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events, Platelet Count, Radiographic Findings

  • Treatment

    Vaccine

  • Trial Participants

    20

British Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

British Columbia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Viral Load or Clearance

  • Treatment

    Hygeine, SOC

  • Trial Participants

    81

British Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    200

British Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    50

British Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization

  • Treatment

    HCQ, SOC

  • Trial Participants

    70

British Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1200

British Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    LPV/r, SOC

  • Trial Participants

    2900

British Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    100

British Columbia
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress

  • Treatment

    LPV/r, SOC

  • Trial Participants

    1220

British Columbia
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    ARBs, SOC

  • Trial Participants

    1372

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, PaO2-FiO2, Radiographic Findings, Hypoxia

  • Treatment

    Siltuximab, TCZ

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, PaO2-FiO2, Radiographic Findings, Hypoxia, Distress

  • Treatment

    Other, SOC

  • Trial Participants

    81

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    230

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events, Serious Adverse Events

  • Treatment

    HCQ

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, D-Dimer, Procalcitonin, ECG

  • Treatment

    Immunomodulators

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Respiratory Rate, Radiographic Findings

  • Treatment

    SOC, TCZ

  • Trial Participants

    60

Brussels
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Creatinine Phosphokinase, eGFR, Troponin, ALT, AST, Bilirubin, Glucose, ECG, 6-Minute Walking Distance, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    AZT, SOC

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS

  • Treatment

    Stem cells

  • Trial Participants

    20

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    200

Brussels
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1045

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    PaO2-FiO2

  • Treatment

    Cytokine removal, SOC

  • Trial Participants

    24

Brussels
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    260

Brussels
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), Angiotensins, PaO2-FiO2, Radiographic Findings

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    60

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    3100

Brussels
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Hyper-Inflammation, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, eGFR, Troponin, Fibrinogen, ALT, AST, Albumin, Bilirubin, Glucose, LDH, Radiographic Findings, Cardiac Outcome (Unspecified)

  • Treatment

    Anticoagulants + Anakinra + Other, SOC

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, D-Dimer, Procalcitonin, Blood Gas, PaO2-FiO2, SpO2, Radiographic Findings, Hypoxia, Cardiac Outcome (Unspecified)

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Radiographic Findings, Hypoxia

  • Treatment

    Anakinra, Anakinra + Siltuximab, Anakinra + TCZ, Siltuximab, SOC, TCZ

  • Trial Participants

    342

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    Other

  • Trial Participants

    80

Brussels
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    284

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Serious Adverse Events, Coagulation Test

  • Treatment

    Other, SOC

  • Trial Participants

    60

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Brussels
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    ARBs, SOC

  • Trial Participants

    1372

Brussels
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    483

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2

  • Treatment

    HCQ, SOC

  • Trial Participants

    8

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Other, SOC

  • Trial Participants

    310

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Ferritin, IL-2, IL-7, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Interferon (Any), MCP-1, MIP-1, White Blood Cell Count, Lymphocyte Count, PaO2-FiO2, SpO2, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    NA

Brussels
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    465

Bucharest
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    682

Bucharest
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Bucharest
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    222

Bucharest
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Bucharest
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Pneumonia or ARDS, Non-invasive Ventilation, Cough, Fever

  • Treatment

    FPV, SOC

  • Trial Participants

    256

Bucharest
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Budapest
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge

  • Treatment

    Other, SOC

  • Trial Participants

    120

Budapest
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Budapest
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Labor Absenteeism, Fever

  • Treatment

    SOC, Vaccine

  • Trial Participants

    NA

Budapest
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Other Mild Symptoms, Bilirubin

  • Treatment

    Plasma based therapy

  • Trial Participants

    20

Budapest
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospitalization, Other Mild Symptoms

  • Treatment

    Education, Psychological therapy

  • Trial Participants

    7576

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge

  • Treatment

    Other, SOC

  • Trial Participants

    140

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Device

  • Trial Participants

    50

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Ferritin, D-Dimer, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    333

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    420

Buenos Aires
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Dexamethasone, SOC

  • Trial Participants

    284

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Antivirals, SOC

  • Trial Participants

    135

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Buenos Aires
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Colchicine, SOC

  • Trial Participants

    2500

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Lymphocyte Count, D-Dimer

  • Treatment

    Other, SOC

  • Trial Participants

    68

Buenos Aires
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    NRTIs, SOC

  • Trial Participants

    1378

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    80

Buenos Aires
  • COVID-19 status

    NA

  • Outcome

    Serious Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    43998

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Respiratory Rate

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    210

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Igs, SOC

  • Trial Participants

    242

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    SOC, Vitamins

  • Trial Participants

    1265

Buenos Aires
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    60000

Buenos Aires
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), Adverse Events, Lymphocyte Count

  • Treatment

    NSAIDs

  • Trial Participants

    40

Buenos Aires
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    400

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    177

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Buenos Aires
  • COVID-19 status

    Suspected

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Anticoagulants

  • Trial Participants

    200

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Buenos Aires
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Troponin, LDH, Urine Sample

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    400

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events, Antibodies

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    45

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Plasma-based therapy, SOC

  • Trial Participants

    36

Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Plasma based therapy

  • Trial Participants

    200

Burgos
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Burgos
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Bursa
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    SOC, Vaccine

  • Trial Participants

    200

Cairo
  • COVID-19 status

    Confirmed, Suspected Or Healthy

  • Outcome

    NA

  • Treatment

    Nutrition, SOC

  • Trial Participants

    60

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Plasma based therapy, Plasma based therapy + Other, SOC

  • Trial Participants

    15

Cairo
  • COVID-19 status

    NA

  • Outcome

    LDH

  • Treatment

    Other, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    PaO2-FiO2

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Healthy

  • Outcome

    Cough, Fever

  • Treatment

    SOC, Vaccine

  • Trial Participants

    200

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any), PAI-1, von Wildebrandt Factor, Lymphocyte Count, Angiotensins, ACE, ACE-II, Surfactant Factor Protein, SRAGE, PaO2-FiO2, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    24

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Distress

  • Treatment

    Dexamethasone

  • Trial Participants

    450

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization

  • Treatment

    DAA, Oseltamivir + HCQ + AZT

  • Trial Participants

    250

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    30

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    FPV, SOC

  • Trial Participants

    90

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Other, SOC

  • Trial Participants

    200

Cairo
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Radiographic Findings

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    60

Cairo
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-1, IL-6, Interferon (Any), Erythrocyte Sedimentation Rate, D-Dimer

  • Treatment

    Other, SOC

  • Trial Participants

    1000

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    67

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, IL-1, Tumor Necrosis Factor (Any), Respiratory Rate

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    200

Cairo
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    200

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ + Antivirals, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Antivirals + AZT, Ivermectin + Antivirals, Ivermectin + Antivirals + AZT, Ivermectin + HCQ

  • Trial Participants

    80

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Radiographic Findings

  • Treatment

    FPV, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress

  • Treatment

    Anticoagulants

  • Trial Participants

    50

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Cough

  • Treatment

    HCQ, SOC

  • Trial Participants

    40

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, Stem cells

  • Trial Participants

    100

Cairo
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer

  • Treatment

    Other

  • Trial Participants

    56

Cairo
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Other Mild Symptoms

  • Treatment

    Other, SOC

  • Trial Participants

    300

Cairo
  • COVID-19 status

    NA

  • Outcome

    Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Blood pH

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    60

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Antivirals, HCQ, Ivermectin

  • Trial Participants

    300

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    HCQ, Ivermectin + Docycline

  • Trial Participants

    200

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    DAA, DAA + Antiviral, SOC

  • Trial Participants

    60

Cairo
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance

  • Treatment

    Other

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Dyspnea

  • Treatment

    HCQ + AZT, Other

  • Trial Participants

    60

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    50

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    360

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Antivirals, DAA, SOC

  • Trial Participants

    240

Cairo
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Other

  • Trial Participants

    200

Cairo
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events

  • Treatment

    NA

  • Trial Participants

    120

Cairo
  • COVID-19 status

    NA

  • Outcome

    Mortality, Ferritin, IL-6, Tumor Necrosis Factor (Any), Platelet Count, Prothrombin, INR, Respiratory Rate

  • Treatment

    Ivermectin + Antivirals, Non-invasive respiratory support

  • Trial Participants

    100

Cairo
  • COVID-19 status

    NA

  • Outcome

    Mortality, Viral Load or Clearance, Ferritin, IL-6, Tumor Necrosis Factor (Any), Prothrombin, PaO2-FiO2, Respiratory Rate

  • Treatment

    HCQ + Antivirals, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Fever

  • Treatment

    Other, SOC

  • Trial Participants

    24

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    HCQ, HCQ + Zinc

  • Trial Participants

    200

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    40

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    60

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Fever, Radiographic Findings

  • Treatment

    Nutrition, SOC

  • Trial Participants

    1000

Cairo
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    45000

Cairo
  • COVID-19 status

    Healthy

  • Outcome

    Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    340

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Other, SOC

  • Trial Participants

    150

Cairo
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance

  • Treatment

    SOC, Vaccine

  • Trial Participants

    900

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Radiographic Findings

  • Treatment

    Plasma based therapy

  • Trial Participants

    20

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Procalcitonin

  • Treatment

    Plasma based therapy

  • Trial Participants

    10

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other

  • Trial Participants

    180

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Ivermectin + Antivirals, SOC

  • Trial Participants

    100

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, C-Reactive Protein, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer

  • Treatment

    Hormone therapy, Hormone therapy + Other, SOC

  • Trial Participants

    160

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS

  • Treatment

    DAA, SOC

  • Trial Participants

    50

Cairo
  • COVID-19 status

    Resolved

  • Outcome

    NA

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    50

Cairo
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance

  • Treatment

    HCQ

  • Trial Participants

    200

Cairo
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, IL-10, Tumor Necrosis Factor (Any), Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, Prothrombin, ALT, AST, Albumin, Bilirubin, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Respiratory Rate, Radiographic Findings

  • Treatment

    Nutrition, SOC

  • Trial Participants

    516

California
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    DHODH inhibitor, SOC

  • Trial Participants

    100

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

California
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events

  • Treatment

    HCQ, HCQ + AZT, SOC

  • Trial Participants

    20

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    479

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

California
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    200

California
  • COVID-19 status

    Confirmed

  • Outcome

    ECG, SpO2

  • Treatment

    Respiratory support

  • Trial Participants

    50

California
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

California
  • COVID-19 status

    Healthy

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1800

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    100

California
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

California
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    mAb, SOC

  • Trial Participants

    390

California
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission

  • Treatment

    ACEi, SOC

  • Trial Participants

    560

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1230

California
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy

  • Trial Participants

    30

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    120

California
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, D-Dimer, Troponin, Cardiac Outcome (Unspecified)

  • Treatment

    Colchicine, SOC

  • Trial Participants

    150

California
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    4000

California
  • COVID-19 status

    Confirmed

  • Outcome

    Platelet Count, ALT, AST, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen

  • Treatment

    HCQ + AZT, HCQ + AZT + LPV/r

  • Trial Participants

    200

California
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

California
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia

  • Treatment

    Other, SOC

  • Trial Participants

    24

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    160

California
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    Natural Killer Cells, SOC

  • Trial Participants

    86

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    46

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    66

California
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    600

California
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    NA

  • Trial Participants

    200

California
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

California
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Adverse Events, C-Reactive Protein

  • Treatment

    Other, SOC

  • Trial Participants

    400

California
  • COVID-19 status

    Confirmed

  • Outcome

    Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Stem cells

  • Trial Participants

    9

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Adverse Events

  • Treatment

    Antirheumatic, SOC

  • Trial Participants

    1000

California
  • COVID-19 status

    NA

  • Outcome

    Mortality, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1300

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir

  • Trial Participants

    1500

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH

  • Treatment

    Colchicine, SOC

  • Trial Participants

    6000

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

California
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Plasma-based therapy, SOC

  • Trial Participants

    96

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Hormone therapy, SOC

  • Trial Participants

    198

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1344

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

California
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other

  • Trial Participants

    18

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin

  • Treatment

    mAb, SOC

  • Trial Participants

    270

California
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    IFN, SOC

  • Trial Participants

    120

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + mAb

  • Trial Participants

    200

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

California
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Fever, Adverse Events, Anti SARS-COV-2 Titers

  • Treatment

    Hygiene

  • Trial Participants

    45

California
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    24

California
  • COVID-19 status

    Healthy

  • Outcome

    IgG, IgM or IgA

  • Treatment

    Vaccine

  • Trial Participants

    180

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Serious Adverse Events

  • Treatment

    Stem cells

  • Trial Participants

    20

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    50

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    52

California
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings

  • Treatment

    mAb, SOC

  • Trial Participants

    86

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events

  • Treatment

    Razuprotafib, SOC

  • Trial Participants

    180

California
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies

  • Treatment

    mAb, SOC

  • Trial Participants

    50

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia

  • Treatment

    Inhaled solution, SOC

  • Trial Participants

    144

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Troponin, Procalcitonin, LDH, SpO2, Respiratory Rate, Hypoxemia

  • Treatment

    Other, SOC

  • Trial Participants

    100

California
  • COVID-19 status

    NA

  • Outcome

    Fever, Antibodies, CD4, CD8, Respiratory Rate

  • Treatment

    Vaccine

  • Trial Participants

    35

California
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, D-Dimer, Electrolytes

  • Treatment

    Ivermectin + Doxycycline + Zinc + Vitamins, Vitamins + Zinc

  • Trial Participants

    300

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    61

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

California
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    mAb

  • Trial Participants

    NA

California
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, IL-1, IL-6, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    60

California
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance

  • Treatment

    Hygiene

  • Trial Participants

    150

California
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Serious Adverse Events

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    600

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    500

California
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    40

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    150

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    410

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

California
  • COVID-19 status

    Confirmed

  • Outcome

    Antibodies

  • Treatment

    Other, SOC

  • Trial Participants

    120

California
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, Vitamins

  • Trial Participants

    829

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any)

  • Treatment

    mAb, SOC

  • Trial Participants

    573

California
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Radiographic Findings

  • Treatment

    NA

  • Trial Participants

    600

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

California
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

California
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events

  • Treatment

    HCQ + Vitamins + Zinc, SOC

  • Trial Participants

    600

California
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    380

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    500

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    60

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings

  • Treatment

    PDE4 + SOC, SOC

  • Trial Participants

    700

California
  • COVID-19 status

    Healthy

  • Outcome

    Labor Absenteeism, Serious Adverse Events

  • Treatment

    Nutrition

  • Trial Participants

    500

California
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Treatment-emergent Adverse Events, IgG, IgM or IgA

  • Treatment

    Other

  • Trial Participants

    60

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

California
  • COVID-19 status

    Confirmed

  • Outcome

    Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    30

California
  • COVID-19 status

    Confirmed

  • Outcome

    Fever

  • Treatment

    Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone

  • Trial Participants

    525

California
  • COVID-19 status

    NA

  • Outcome

    Mortality

  • Treatment

    Plasma based therapy

  • Trial Participants

    60

California
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    mAb, SOC

  • Trial Participants

    300

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation

  • Treatment

    mAb, SOC

  • Trial Participants

    17

California
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin

  • Treatment

    Other, SOC

  • Trial Participants

    30

California
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    208

Callao
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Callao
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Cambridgeshire
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, D-Dimer, LDH, Renal Outcome (Unspecified)

  • Treatment

    Other, SGLT2 + Other, SOC

  • Trial Participants

    1407

Cambridgeshire
  • COVID-19 status

    Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    JAKi, mAb, SOC

  • Trial Participants

    1167

Cambridgeshire
  • COVID-19 status

    Healthy

  • Outcome

    Mortality

  • Treatment

    HCQ, SOC

  • Trial Participants

    1500

Canberra
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    ICU Admission, Fever, Treatment-emergent Adverse Events, Blood Gas, PaO2-FiO2

  • Treatment

    SOC, Stem cells

  • Trial Participants

    24

Canberra
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Depression, Anxiety

  • Treatment

    Psychological therapy + Nutrition + Exercise

  • Trial Participants

    40

Canberra
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    3468

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    682

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    230

Canberra
  • COVID-19 status

    NA

  • Outcome

    Other Mild Symptoms

  • Treatment

    Other

  • Trial Participants

    100

Canberra
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance

  • Treatment

    Hygiene

  • Trial Participants

    20

Canberra
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers

  • Treatment

    Stem cells

  • Trial Participants

    24

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    SpO2

  • Treatment

    Positioning, SOC

  • Trial Participants

    20

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Adverse Events, Blood Pressure, Radiographic Findings

  • Treatment

    ARBs, SOC

  • Trial Participants

    36

Canberra
  • COVID-19 status

    Healthy

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    HCQ

  • Trial Participants

    680

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Canberra
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1419

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Non-invasive Ventilation

  • Treatment

    HCQ + LPV/r, HCQ + LPV/r + Plasma based therapy, LPV/r, LPV/r + Plasma based therapy, Plasma based therapy, SOC

  • Trial Participants

    2400

Canberra
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Blood Gas, PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    160

Canberra
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality

  • Treatment

    HCQ, SOC

  • Trial Participants

    400

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Serious Adverse Events

  • Treatment

    Other + Alternative therapy

  • Trial Participants

    30

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + HCQ

  • Trial Participants

    2500

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    FPV, SOC

  • Trial Participants

    190

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + Zinc + Vitamins + AZT

  • Trial Participants

    200

Canberra
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    2250

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Adverse Events

  • Treatment

    Device

  • Trial Participants

    20

Canberra
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, PaO2-FiO2

  • Treatment

    SOC, Stem cells

  • Trial Participants

    40

Canberra
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    216

Canberra
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    1000

Canberra
  • COVID-19 status

    NA

  • Outcome

    Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2

  • Treatment

    SOC, Zinc

  • Trial Participants

    160

Canberra
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Anti SARS-COV-2 Titers

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    1000

Canberra
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    NA

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    206

Canberra
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, TCZ

  • Trial Participants

    150

Cantabria
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Cantabria
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Colchicine, SOC

  • Trial Participants

    1028

Catania
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings

  • Treatment

    TCZ

  • Trial Participants

    400

Catania
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Anticoagulants

  • Trial Participants

    300

Catanzaro
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Lymphocyte Count

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    400

Catanzaro
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    120

Ceara
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Celje
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, HCQ + Other

  • Trial Participants

    90

Chandigarh
  • COVID-19 status

    NA

  • Outcome

    Serious or Seconday Infections, Adverse Events, Serious Adverse Events

  • Treatment

    Other

  • Trial Participants

    4000

Chandigarh
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events, Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    480

Chandigarh
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Other, SOC

  • Trial Participants

    40

Chandigarh
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    325

Chelyabinsk
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Cher
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings

  • Treatment

    HCQ, SOC

  • Trial Participants

    259

Chhattisgarh
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Other, SOC

  • Trial Participants

    40

Chiba
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Chiba
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    ARBs, SOC

  • Trial Participants

    1372

Chieti
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Chieti
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    182

Chisinau
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    222

Chisinau
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Chisinau
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Chongqing
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events

  • Treatment

    Natural Killer Cells

  • Trial Participants

    90

Chongqing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    368

Chongqing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Antivirals + IFN, Antivirals + LPV/r + IFN, LPV/r + IFN

  • Trial Participants

    108

Chongqing
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    48

Chongqing
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    50

Chongqing
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    IFN + Other, LPV/r + IFN, Umifenovir + IFN

  • Trial Participants

    60

City
  • COVID-19 status

    NA

  • Outcome

    Mortality, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1300

City
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

City
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Ciudad De Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Ciudad De Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Ciudad De Buenos Aires
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Troponin, LDH, Urine Sample

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    400

Ciudad De Buenos Aires
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events, Antibodies

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    45

Ciudad Real
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG

  • Treatment

    Other

  • Trial Participants

    46

Ciudad Real
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Cluj
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Pneumonia or ARDS, Non-invasive Ventilation, Cough, Fever

  • Treatment

    FPV, SOC

  • Trial Participants

    256

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    479

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Colorado
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1230

Colorado
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    4000

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    10

Colorado
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    600

Colorado
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Quality of Life, Renal Outcome (Unspecified)

  • Treatment

    Dexamethasone, SOC

  • Trial Participants

    90

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir

  • Trial Participants

    1500

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Hemoglobin, Creatinine Phosphokinase, Prothrombin, ALT, Bilirubin, Glucose

  • Treatment

    JAKi

  • Trial Participants

    80

Colorado
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)

  • Treatment

    NA

  • Trial Participants

    80

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    702

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, Blood Pressure, Renal Outcome (Unspecified)

  • Treatment

    Other, SOC

  • Trial Participants

    100

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    600

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    40

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Colorado
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2, Patient Positioning

  • Treatment

    Positioning

  • Trial Participants

    100

Colorado
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1000

Conakry
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    3000

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Connecticut
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Connecticut
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

Connecticut
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    300

Connecticut
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    Antibiotics

  • Trial Participants

    NA

Connecticut
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospitalization

  • Treatment

    Other, SOC

  • Trial Participants

    60

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir

  • Trial Participants

    1500

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1344

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6

  • Treatment

    Other, SOC

  • Trial Participants

    100

Connecticut
  • COVID-19 status

    NA

  • Outcome

    Mortality, Viral Load or Clearance, Antibodies

  • Treatment

    Plasma based therapy

  • Trial Participants

    48

Connecticut
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings

  • Treatment

    mAb, SOC

  • Trial Participants

    86

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    60

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Nutrition, SOC

  • Trial Participants

    1500

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    D-Dimer

  • Treatment

    Other, SOC

  • Trial Participants

    200

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    142

Connecticut
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Adverse Events

  • Treatment

    DHODH inhibitor, SOC

  • Trial Participants

    24

Connecticut
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms

  • Treatment

    Other, SOC

  • Trial Participants

    114

Copenhagen
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    1100

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein

  • Treatment

    Sarilumab, TCZ

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Visits or Returns to Emergency Department, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH, Quality of Life

  • Treatment

    AZT, HCQ, SOC

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Shock, Quality of Life, Renal Outcome (Unspecified)

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    440

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1230

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge

  • Treatment

    Other, SOC

  • Trial Participants

    120

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life

  • Treatment

    SOC, TCZ

  • Trial Participants

    450

Copenhagen
  • COVID-19 status

    NA

  • Outcome

    Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Coagulation Test, Bilirubin, PaO2-FiO2, Renal Outcome (Unspecified)

  • Treatment

    Other

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    80

Copenhagen
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    HCQ, JAKi, Sarilumab, SOC

  • Trial Participants

    1500

Copenhagen
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)

  • Treatment

    Positioning

  • Trial Participants

    150

Copenhagen
  • COVID-19 status

    NA

  • Outcome

    Mortality

  • Treatment

    JAKi

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Blood Gas, Blood pH

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    226

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Copenhagen
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Labor Absenteeism, Fever, Other Mild Symptoms

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1500

Copenhagen
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Labor Absenteeism, Fever

  • Treatment

    SOC, Vaccine

  • Trial Participants

    NA

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein

  • Treatment

    Sarilumab, SOC, TCZ

  • Trial Participants

    20

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Respiratory support, SOC

  • Trial Participants

    400

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Non-invasive Ventilation

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    400

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    580

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, Vitamins

  • Trial Participants

    100

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, LDH

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    200

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Quality of Life

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    1000

Copenhagen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Copenhagen
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Antibodies

  • Treatment

    NA

  • Trial Participants

    6000

Cordoba
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Cordoba
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events

  • Treatment

    SOC, Vitamins

  • Trial Participants

    1008

Cordoba
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Cornwall
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Corrientes
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Corrientes
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    500

Cosenza
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Lymphocyte Count

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    400

Cosenza
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings

  • Treatment

    TCZ

  • Trial Participants

    400

Cremona
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Cremona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Cremona
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Anticoagulants

  • Trial Participants

    300

Cross River
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any)

  • Treatment

    Nutrition, SOC

  • Trial Participants

    90

Cuenca
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Cumbria
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Cundinamarca
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA

  • Treatment

    HCQ + AZT, Plasma based therapy + HCQ + AZT

  • Trial Participants

    90

Cundinamarca
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Cundinamarca
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA

  • Treatment

    Plasma based therapy

  • Trial Participants

    10

Cundinamarca
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Troponin, Procalcitonin, LDH, PaO2-FiO2

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    236

Cundinamarca
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    60

Daegu
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Daegu
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Dagestan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    mAb, SOC

  • Trial Participants

    204

Dakar
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    HCQ + AZT, Zinc

  • Trial Participants

    384

Dakar
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events

  • Treatment

    HCQ, HCQ + AZT

  • Trial Participants

    186

Delaware
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein, IL-6

  • Treatment

    Other, SOC

  • Trial Participants

    64

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, PaO2-FiO2

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    452

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    50

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, PaO2-FiO2

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    100

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    100

Delhi
  • COVID-19 status

    Suspected

  • Outcome

    NA

  • Treatment

    Alternative therapy

  • Trial Participants

    10000

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    140

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    50000

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy

  • Trial Participants

    50

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    200

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy

  • Trial Participants

    40

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    40000

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    400

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Radiation therapy

  • Trial Participants

    10

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    120

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Exercise + Alternative therapy, SOC

  • Trial Participants

    452

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    300

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    100

Delhi
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospital Discharge, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Positioning

  • Trial Participants

    20

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Other, SOC

  • Trial Participants

    40

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    Antibodies

  • Treatment

    Psychological therapy, SOC

  • Trial Participants

    250

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    800

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy

  • Trial Participants

    500

Delhi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy + Hygiene+ Exercise + Psychological therapy

  • Trial Participants

    425

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    ARBs, SOC

  • Trial Participants

    605

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    100

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    96

Delhi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Delhi
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Viral Load or Clearance

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    61000

Devon
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Dhaka
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Colchicine, SOC

  • Trial Participants

    300

Dhaka
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Ivermectin + Antibiotics, SOC

  • Trial Participants

    400

Dhaka
  • COVID-19 status

    Confirmed

  • Outcome

    Cough, Fever

  • Treatment

    Ivermectin, Ivermectin + Antibiotics, SOC

  • Trial Participants

    72

Dhaka
  • COVID-19 status

    Confirmed

  • Outcome

    Radiographic Findings

  • Treatment

    FPV, SOC

  • Trial Participants

    50

Dhaka
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    20

Dhaka
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    60

Dhaka
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Fever, C-Reactive Protein, SpO2, Respiratory Rate

  • Treatment

    Antibiotics, SOC

  • Trial Participants

    94

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    208

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2

  • Treatment

    mAb, SOC

  • Trial Participants

    384

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

District Of Columbia
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    46

District Of Columbia
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    Antibiotics

  • Trial Participants

    NA

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

District Of Columbia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospitalization

  • Treatment

    mAb, SOC

  • Trial Participants

    376

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    80

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    52

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events

  • Treatment

    Razuprotafib, SOC

  • Trial Participants

    180

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    61

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    500

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Fever

  • Treatment

    Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone

  • Trial Participants

    525

District Of Columbia
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Distrito Federal
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life

  • Treatment

    HCQ, HCQ + AZT

  • Trial Participants

    440

Distrito Federal
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

Distrito Federal
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Dexamethasone, SOC

  • Trial Participants

    299

Distrito Federal
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2

  • Treatment

    HCQ, SOC

  • Trial Participants

    630

Dodoma
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    3000

Doha
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    HCQ, HCQ + AZT, SOC

  • Trial Participants

    456

Doha
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    NA

  • Treatment

    Vasodilators

  • Trial Participants

    40

Doha
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Doha
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Device, SOC

  • Trial Participants

    20

Doha
  • COVID-19 status

    Confirmed

  • Outcome

    PaO2-FiO2, Renal Outcome (Unspecified)

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    100

Doha
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    500

Doha
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Dublin
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), PaO2-FiO2, Shock, Renal Outcome (Unspecified)

  • Treatment

    Other

  • Trial Participants

    36

Dublin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, PaO2-FiO2

  • Treatment

    HCQ, HCQ + AZT, SOC

  • Trial Participants

    267

Dublin
  • COVID-19 status

    NA

  • Outcome

    Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Respiratory Rate, Patient Positioning

  • Treatment

    Positioning, SOC

  • Trial Participants

    200

Dublin
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Serious Adverse Events, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    90

Dublin
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

Dublin
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Dublin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Non-invasive Ventilation, C-Reactive Protein, Ferritin, IL-6, D-Dimer, LDH, Radiographic Findings, Shock

  • Treatment

    SOC, TCZ

  • Trial Participants

    90

Dudley
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    150

Dudley
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Dundee
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Pneumonia or ARDS

  • Treatment

    AZT, SOC

  • Trial Participants

    800

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    SOC, Vitamins

  • Trial Participants

    30

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein, White Blood Cell Count, Respiratory Rate

  • Treatment

    NA

  • Trial Participants

    60

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    200

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    86

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events, ALT

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    110

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    60

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Radiographic Findings

  • Treatment

    HCQ + LPV/r + Antivirals, Igs + HCQ + LPV/r + Antivirals

  • Trial Participants

    100

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Radiographic Findings

  • Treatment

    Dialysis

  • Trial Participants

    10

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Plasma based therapy

  • Trial Participants

    30

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    HCQ + LPV/r, HCQ + LPV/r + Other

  • Trial Participants

    60

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    Fever, Other Mild Symptoms, C-Reactive Protein, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    10

East Azarbaijan
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance

  • Treatment

    HCQ, SOC

  • Trial Participants

    500

East Azarbaijan
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    300

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein

  • Treatment

    Other, SOC

  • Trial Participants

    40

East Azarbaijan
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, SpO2, Respiratory Rate, Radiographic Findings

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    80

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    30

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    80

East Azarbaijan
  • COVID-19 status

    Confirmed

  • Outcome

    Organ Failure or Dysfunction (SOFA), Platelet Count, Coagulation Test, Bilirubin, PaO2-FiO2, Renal Outcome (Unspecified)

  • Treatment

    HCQ, HCQ + Raltagravir, HCQ + Raltagravir + IFN

  • Trial Participants

    60

East Sussex
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Edinburgh
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Edinburgh
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Viral Load or Clearance, Adverse Events, Coagulation Test, SpO2, Renal Outcome (Unspecified)

  • Treatment

    Anticoagulants, Other, SOC

  • Trial Participants

    60

Edinburgh
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Edinburgh
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    389

Espirito Santo
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life

  • Treatment

    HCQ, HCQ + AZT

  • Trial Participants

    440

Espirito Santo
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, D-Dimer, Troponin

  • Treatment

    Anticoagulants

  • Trial Participants

    600

Essex
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Fars
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Respiratory Rate

  • Treatment

    NA

  • Trial Participants

    374

Fars
  • COVID-19 status

    Suspected

  • Outcome

    Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    60

Fars
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Corticosteroids + Igs + IFN, HCQ + Antivirals

  • Trial Participants

    105

Fars
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Vaccine

  • Trial Participants

    130000

Fars
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Fever, SpO2

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    60

Fars
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2

  • Treatment

    HCQ + LPV/r, LPV/r + HCQ + Other

  • Trial Participants

    30

Firenze
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    DHODH inhibitor, SOC

  • Trial Participants

    100

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    479

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Florida
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    200

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Anticoagulants, Antihypertensive, SOC

  • Trial Participants

    7000

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    100

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    436

Florida
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1230

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission

  • Treatment

    SOC, Stem cells

  • Trial Participants

    70

Florida
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

Florida
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia

  • Treatment

    Other, SOC

  • Trial Participants

    24

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    mAb, SOC

  • Trial Participants

    124

Florida
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    300

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    66

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    46

Florida
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    600

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Adverse Events

  • Treatment

    Antirheumatic, SOC

  • Trial Participants

    1000

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH

  • Treatment

    Colchicine, SOC

  • Trial Participants

    6000

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Hormone therapy, SOC

  • Trial Participants

    198

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1344

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin

  • Treatment

    mAb, SOC

  • Trial Participants

    270

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, D-Dimer, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    20

Florida
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Fever, Organ Failure or Dysfunction (SOFA), SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Other, SOC

  • Trial Participants

    252

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, CD4, CD8

  • Treatment

    Other, SOC

  • Trial Participants

    48

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, D-Dimer

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    241

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    264

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    300

Florida
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance

  • Treatment

    FPV, SOC

  • Trial Participants

    50

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia

  • Treatment

    Inhaled solution, SOC

  • Trial Participants

    144

Florida
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    260

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Other, SOC

  • Trial Participants

    40

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Florida
  • COVID-19 status

    NA

  • Outcome

    Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Dyspnea, PaO2-FiO2, 6-Minute Walking Distance

  • Treatment

    Inhaled solution, SOC

  • Trial Participants

    288

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    61

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    702

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    SOC, Vitamins, Vitamins + Zinc, Zinc

  • Trial Participants

    520

Florida
  • COVID-19 status

    NA

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, D-Dimer, Troponin, Antibodies

  • Treatment

    SOC, Stem cells

  • Trial Participants

    24

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Serious Adverse Events

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    600

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    500

Florida
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality

  • Treatment

    SOC, Vaccine

  • Trial Participants

    96

Florida
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2

  • Treatment

    ARBs

  • Trial Participants

    200

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, SpO2

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    280

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2

  • Treatment

    Merimepodib + Remdesivir, Remdesivir

  • Trial Participants

    80

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    410

Florida
  • COVID-19 status

    Suspected

  • Outcome

    NA

  • Treatment

    Antivirals + Vitamins, Vitamins

  • Trial Participants

    800

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

Florida
  • COVID-19 status

    NA

  • Outcome

    IL-6, Glucose, SpO2

  • Treatment

    DPP-4i, SOC

  • Trial Participants

    20

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, Vitamins

  • Trial Participants

    160

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, CD4, CD8

  • Treatment

    Other, SOC

  • Trial Participants

    48

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Adverse Events

  • Treatment

    DHODH inhibitor, SOC

  • Trial Participants

    24

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    500

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Electrolytes, LDH

  • Treatment

    SOC, Stem cells

  • Trial Participants

    21

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Fever

  • Treatment

    Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone

  • Trial Participants

    525

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    100

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    mAb, SOC

  • Trial Participants

    300

Florida
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Foggia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Anticoagulants

  • Trial Participants

    300

Fujian
  • COVID-19 status

    Resolved

  • Outcome

    Quality of Life

  • Treatment

    Respiratory support

  • Trial Participants

    80

Fujian
  • COVID-19 status

    Confirmed

  • Outcome

    IL-6, Quality of Life, Distress

  • Treatment

    Respiratory support, SOC

  • Trial Participants

    80

Fujian
  • COVID-19 status

    Healthy

  • Outcome

    Quality of Life

  • Treatment

    Respiratory support, SOC

  • Trial Participants

    80

Fujian
  • COVID-19 status

    NA

  • Outcome

    C-Reactive Protein, IL-10, Tumor Necrosis Factor (Any), CD4, CD8, Blood Gas, PaO2-FiO2

  • Treatment

    Oseltamivir + Non-invasive respiratory support + Hormone therapy, Stem cells + Oseltamivir + Non-invasive respiratory support + Hormone therapy

  • Trial Participants

    60

Fujian
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious Adverse Events, Heart Rate, Respiratory Rate

  • Treatment

    HCQ, SOC

  • Trial Participants

    100

Fujian
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Viral Load or Clearance, Fever, Serious Adverse Events, Respiratory Rate

  • Treatment

    HCQ, SOC

  • Trial Participants

    100

Fukuoka
  • COVID-19 status

    NA

  • Outcome

    Serious Adverse Events

  • Treatment

    Vaccine

  • Trial Participants

    256

Galway
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Troponin

  • Treatment

    Antihypertensive

  • Trial Participants

    2414

Gauteng
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    40

Gauteng
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Gauteng
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

Gauteng
  • COVID-19 status

    NA

  • Outcome

    Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    2000

Gaziantep
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Other, SOC

  • Trial Participants

    200

Gaziantep
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Gelderland
  • COVID-19 status

    Resolved

  • Outcome

    Other Mild Symptoms, 6-Minute Walking Distance

  • Treatment

    Rehabilitation

  • Trial Participants

    40

Gelderland
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1500

Gelderland
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Secondary CoViD-19 Re-infection, Fever, Other Mild Symptoms

  • Treatment

    SOC, Vaccine

  • Trial Participants

    2014

Geneve
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    3000

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    DHODH inhibitor, SOC

  • Trial Participants

    100

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Blood pH, Bicarbonates

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    2

Georgia
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    200

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

Georgia
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    mAb, SOC

  • Trial Participants

    390

Georgia
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1230

Georgia
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    4000

Georgia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia

  • Treatment

    Other, SOC

  • Trial Participants

    24

Georgia
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    600

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH

  • Treatment

    Remdesivir, Remdesivir + mAb

  • Trial Participants

    200

Georgia
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospitalization

  • Treatment

    mAb, SOC

  • Trial Participants

    376

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin

  • Treatment

    mAb, SOC

  • Trial Participants

    270

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    mAb, SOC

  • Trial Participants

    124

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + mAb

  • Trial Participants

    200

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    24

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    52

Georgia
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings

  • Treatment

    mAb, SOC

  • Trial Participants

    86

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    702

Georgia
  • COVID-19 status

    NA

  • Outcome

    C-Reactive Protein, Ferritin, IL-6, Hemoglobin, D-Dimer, eGFR, Myoglobin, Troponin, Procalcitonin, Fibrinogen, Triglycerides, ALT, AST, Albumin, Bilirubin, LDH, Blood Gas, Blood Pressure, Heart Rate, Radiographic Findings, Blood pH

  • Treatment

    Radiation therapy

  • Trial Participants

    10

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, Fibrinogen, INR, Albumin, Bilirubin, Blood Urea Nitrogen, Blood Pressure, Heart Rate, Respiratory Rate

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    20

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization

  • Treatment

    HCQ, SOC

  • Trial Participants

    700

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, CD8

  • Treatment

    Vaccine

  • Trial Participants

    32

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    380

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    30

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    mAb, SOC

  • Trial Participants

    300

Georgia
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Gerona
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Gibraltar
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), C-Reactive Protein, Troponin

  • Treatment

    Colchicine, SOC

  • Trial Participants

    180

Glasgow
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Glasgow
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Goias
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life

  • Treatment

    HCQ, HCQ + AZT

  • Trial Participants

    440

Goias
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Golestan
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance

  • Treatment

    NA

  • Trial Participants

    45

Golestan
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    60

Golestan
  • COVID-19 status

    Confirmed

  • Outcome

    Platelet Count, Radiographic Findings

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    50

Granada
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Granada
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Granada
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Pneumonia or ARDS, Cough, Other Mild Symptoms

  • Treatment

    Nutrition, SOC

  • Trial Participants

    314

Granada
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Greater Accra
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

Greenwich
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Groningen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    426

Groningen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission

  • Treatment

    Plasma-based therapy

  • Trial Participants

    690

Groningen
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2

  • Treatment

    HCQ, SOC

  • Trial Participants

    8

Guadalajara
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG

  • Treatment

    Other

  • Trial Participants

    46

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), Quality of Life

  • Treatment

    Nutrition, SOC

  • Trial Participants

    80

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, ALT, Albumin, Bilirubin, IgG, IgM or IgA, PaO2-FiO2, Respiratory Rate, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    400

Guangdong
  • COVID-19 status

    Resolved

  • Outcome

    Other Mild Symptoms

  • Treatment

    SOC, TCM

  • Trial Participants

    144

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Pneumonia or ARDS, Treatment-emergent Adverse Events

  • Treatment

    SOC, TCM

  • Trial Participants

    204

Guangdong
  • COVID-19 status

    Resolved

  • Outcome

    Clinical Improvement Score (Any), 6-Minute Walking Distance, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    120

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, White Blood Cell Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    300

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Hygiene, SOC

  • Trial Participants

    40

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Radiographic Findings

  • Treatment

    Vaccine

  • Trial Participants

    100

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Anticoagulants, Other

  • Trial Participants

    120

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate

  • Treatment

    SOC, TCM

  • Trial Participants

    120

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Pneumonia or ARDS, ALT

  • Treatment

    IFN + Other, Umifenovir + IFN

  • Trial Participants

    30

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Cough, C-Reactive Protein

  • Treatment

    SOC, TCM

  • Trial Participants

    128

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Treatment-emergent Adverse Events, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    40

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, ALT, Bilirubin, Blood Pressure, Heart Rate, PaO2-FiO2, Respiratory Rate, Radiographic Findings

  • Treatment

    LPV/r, SOC, Umifenovir

  • Trial Participants

    86

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Cough, Dyspnea, SpO2, Distress

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    90

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Respiratory Rate

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    60

Guangdong
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein

  • Treatment

    Vaccine

  • Trial Participants

    100

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    SOC, TCM + Umifenovir

  • Trial Participants

    40

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Erythrocyte Sedimentation Rate

  • Treatment

    Nutrition, SOC

  • Trial Participants

    394

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    200

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS, C-Reactive Protein, IL-2, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer, Myoglobin, Procalcitonin, Electrolytes, Glucose, Blood Gas, Renal Outcome (Unspecified)

  • Treatment

    Other, SOC

  • Trial Participants

    60

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    DAA, FPV

  • Trial Participants

    30

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    SpO2

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    198

Guangdong
  • COVID-19 status

    Healthy

  • Outcome

    Household Members with CoViD-19

  • Treatment

    SOC, TCM

  • Trial Participants

    828

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, Myoglobin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, Renal Outcome (Unspecified)

  • Treatment

    HCQ, LPV/r

  • Trial Participants

    112

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, ALT, Albumin, Bilirubin, Quality of Life

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    440

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein

  • Treatment

    HCQ, SOC

  • Trial Participants

    20

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    FPV + IFN, IFN, LPV/r + IFN

  • Trial Participants

    90

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance

  • Treatment

    HCQ, LPV/r, LPV/r + HCQ

  • Trial Participants

    205

Guangdong
  • COVID-19 status

    NA

  • Outcome

    Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Adverse Events, C-Reactive Protein, CD4, CD8, PaO2-FiO2, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    20

Guangdong
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Fever, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Procalcitonin, ALT, Albumin, Bilirubin, Blood Gas, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    TCM

  • Trial Participants

    72

Guangdong
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, CD4, CD8, Renal Outcome (Unspecified)

  • Treatment

    NA

  • Trial Participants

    300

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein, IL-17, Lymphocyte Count, Blood Gas

  • Treatment

    SOC, Vaccine

  • Trial Participants

    120

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, Neutrophils, Hemoglobin, Urine Sample, IgG, IgM or IgA, Blood Urea Nitrogen

  • Treatment

    NA

  • Trial Participants

    100

Guangdong
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    NA

  • Trial Participants

    60

Guangdong
  • COVID-19 status

    Resolved

  • Outcome

    Dyspnea, Weight, Height or BMI

  • Treatment

    Other, TCM + Other

  • Trial Participants

    150

Guangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    60

Guayas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Guizhou
  • COVID-19 status

    Confirmed

  • Outcome

    CK-MB, LDH

  • Treatment

    Other

  • Trial Participants

    200

Guizhou
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, PaO2-FiO2, Respiratory Rate

  • Treatment

    Respiratory support

  • Trial Participants

    200

Gujarat
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any)

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    200

Gujarat
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Gujarat
  • COVID-19 status

    Confirmed

  • Outcome

    Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any)

  • Treatment

    Other, SOC

  • Trial Participants

    106

Gujarat
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Gujarat
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    48

Gunma
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, C-Reactive Protein

  • Treatment

    FPV

  • Trial Participants

    100

Gunma
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, C-Reactive Protein

  • Treatment

    HCQ + LPV/r, Oseltamivir + HCQ + LPV/r

  • Trial Participants

    50

Gyeonggi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Gyeonggi
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Device, Vaccine + Device

  • Trial Participants

    160

Gyeonggi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Gyeonggi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Haifa
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    50

Haifa
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    582

Haifa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    120

Hamadan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Other, SOC

  • Trial Participants

    92

Hamadan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Corticosteroids, Dexamethasone

  • Trial Participants

    81

Hamburg
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Anticoagulants

  • Trial Participants

    172

Hamburg
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Hamburg
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Hamburg
  • COVID-19 status

    NA

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    220

Hamburg
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Hamburg
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, LDH

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    200

Hamburg
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), Procalcitonin, Bicarbonates, Renal Outcome (Unspecified)

  • Treatment

    Cytokine removal, SOC

  • Trial Participants

    24

Hampshire
  • COVID-19 status

    Confirmed, Suspected Or Healthy

  • Outcome

    Viral Load or Clearance

  • Treatment

    Hygiene, SOC

  • Trial Participants

    40

Hanoi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    250

Hanoi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    44

Hanoi
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Plasma based therapy

  • Trial Participants

    10

Harare
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

Haryana
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    60

Haryana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    SOC, TCZ

  • Trial Participants

    180

Haryana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Haryana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Havana
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Prothrombin, Triglycerides, ALT, Albumin, Bilirubin, Glucose

  • Treatment

    SOC, Vaccine

  • Trial Participants

    80

Havana
  • COVID-19 status

    Confirmed

  • Outcome

    Labor Absenteeism

  • Treatment

    IFN

  • Trial Participants

    120

Havana
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    IFN

  • Trial Participants

    30

Havana
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    mAb

  • Trial Participants

    80

Havana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge

  • Treatment

    Other

  • Trial Participants

    16

Havana
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    115000

Havana
  • COVID-19 status

    Healthy

  • Outcome

    Monocyte Count, Lymphocyte Count, Dendritic Cell Count, CD4, CD8

  • Treatment

    Other

  • Trial Participants

    60

Havana
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    20

Havana
  • COVID-19 status

    Confirmed

  • Outcome

    Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    HCQ + Antivirals + Inferon, Other + HCQ + Antivirals + Inferon

  • Trial Participants

    32

Havana
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Immunomodulators

  • Trial Participants

    NA

Havana
  • COVID-19 status

    Resolved

  • Outcome

    Pneumonia or ARDS

  • Treatment

    Corticosteroids, Stem cells

  • Trial Participants

    20

Hawaii
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    208

Hawaii
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Hawaii
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Hawaii
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Hawaii
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Hawaii
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Heart Rate

  • Treatment

    HCQ, SOC

  • Trial Participants

    350

Hawaii
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO

  • Treatment

    SOC, TCZ

  • Trial Participants

    300

Hebei
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate

  • Treatment

    IFN, SOC

  • Trial Participants

    328

Hebei
  • COVID-19 status

    Suspected

  • Outcome

    Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    240

Hebei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    240

Hebei
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate

  • Treatment

    SOC, TCM

  • Trial Participants

    110

Heilongjiang
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, Urine Sample, Blood Pressure, ECG, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    Other, SOC

  • Trial Participants

    240

Heilongjiang
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    30

Heilongjiang
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Cough, Fever, SpO2, Respiratory Rate, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Depression, Anxiety

  • Treatment

    Respiratory support, SOC

  • Trial Participants

    60

Heilongjiang
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation

  • Treatment

    Other, SOC

  • Trial Participants

    240

Heilongjiang
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, C-Reactive Protein, White Blood Cell Count, Coagulation Test, IgG, IgM or IgA, Antibodies

  • Treatment

    Other, SOC

  • Trial Participants

    350

Helsinki
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    HCQ, Remdesivir, SOC

  • Trial Participants

    NA

Helsinki
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)

  • Treatment

    SOC, TCZ

  • Trial Participants

    90

Henan
  • COVID-19 status

    Resolved

  • Outcome

    Anxiety

  • Treatment

    SOC, TCM

  • Trial Participants

    28

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings

  • Treatment

    TCM

  • Trial Participants

    24

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Depression, Anxiety

  • Treatment

    Psychological therapy

  • Trial Participants

    81

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Procalcitonin, ALT, Albumin, Bilirubin, Glucose, Urine Sample, Radiographic Findings, Depression, Anxiety, Distress

  • Treatment

    Stem cells

  • Trial Participants

    20

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    30

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, CD4, CD8

  • Treatment

    DAA

  • Trial Participants

    10

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, CD8

  • Treatment

    DAA

  • Trial Participants

    30

Henan
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    288

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, Radiographic Findings

  • Treatment

    Antivirals, SOC

  • Trial Participants

    20

Henan
  • COVID-19 status

    Resolved

  • Outcome

    Visits or Returns to Emergency Department, Pneumonia or ARDS, Radiographic Findings, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Pneumonia or ARDS, Fever

  • Treatment

    SOC, TCM

  • Trial Participants

    60

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Treatment-emergent Adverse Events, CD4, CD8, Radiographic Findings

  • Treatment

    Natural Killer Cells, SOC

  • Trial Participants

    30

Henan
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Hertfordshire
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Hessen
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    400

Ho Chi Minh City
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    250

Hong Kong
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Hong Kong
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, IL-1, IL-2, IL-6, Tumor Necrosis Factor (Any)

  • Treatment

    mAb, SOC

  • Trial Participants

    15

Hong Kong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Hong Kong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events

  • Treatment

    HCQ, IFN

  • Trial Participants

    60

Hong Kong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, IL-6, Tumor Necrosis Factor (Any)

  • Treatment

    LPV/r, LPV/r + IFN

  • Trial Participants

    127

Hong Kong
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Adverse Events

  • Treatment

    Antibiotics, IFN + Antibiotics, SOC

  • Trial Participants

    81

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, Troponin, Procalcitonin, ALT, LDH, CD4, CD8, Respiratory Rate, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    20

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Other Mild Symptoms, Stool Sample

  • Treatment

    SOC, TCM

  • Trial Participants

    200

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS, Radiographic Findings, Quality of Life, Depression, Anxiety, Distress

  • Treatment

    Stem cells

  • Trial Participants

    20

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, PaO2-FiO2

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events

  • Treatment

    FPV, Umifenovir

  • Trial Participants

    240

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, CK-MB, ALT, PaO2-FiO2, Radiographic Findings

  • Treatment

    Other

  • Trial Participants

    10

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    96

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Pneumonia or ARDS, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    300

Hubei
  • COVID-19 status

    Healthy

  • Outcome

    Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    108

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Hypoxia

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    60

Hubei
  • COVID-19 status

    NA

  • Outcome

    6-Minute Walking Distance, Radiographic Findings, Quality of Life

  • Treatment

    Education, TCM + Education

  • Trial Participants

    160

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Creatinine Phosphokinase, CK-MB, ALT, Blood Urea Nitrogen

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Hubei
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Interferon (Any), IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    508

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Procalcitonin, ALT, Albumin, Bilirubin

  • Treatment

    LPV/r, SOC

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Glucose, Radiographic Findings

  • Treatment

    TCM

  • Trial Participants

    50

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, PaO2-FiO2, Respiratory Rate, Radiographic Findings

  • Treatment

    Igs, SOC

  • Trial Participants

    10

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    300

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Procalcitonin, PaO2-FiO2, Radiographic Findings

  • Treatment

    Stem cells

  • Trial Participants

    16

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any), White Blood Cell Count, Shock

  • Treatment

    SOC, TCM

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms

  • Treatment

    SOC, TCM

  • Trial Participants

    400

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Serious Adverse Events, Granulocyte Stimulaiting Factor, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Neutrophils, ALT, Albumin, Bilirubin, IgG, IgM or IgA

  • Treatment

    Cyclosporine, HCQ, SOC

  • Trial Participants

    80

Hubei
  • COVID-19 status

    Resolved

  • Outcome

    Clinical Improvement Score (Any), Fever, Antibodies, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    120

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, TCM

  • Trial Participants

    200

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Respiratory Rate

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    SOC, Stem cells

  • Trial Participants

    70

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events

  • Treatment

    LPV/r, SOC

  • Trial Participants

    160

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    86

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Erythrocyte Sedimentation Rate, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    152

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, White Blood Cell Count, Lymphocyte Count, Neutrophils, Antibodies, Radiographic Findings

  • Treatment

    TCM

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Viral Load or Clearance

  • Treatment

    TCM

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    200

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Treatment-emergent Adverse Events

  • Treatment

    IFN, SOC

  • Trial Participants

    328

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    90

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    SOC, TCM

  • Trial Participants

    120

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Dyspnea, SpO2, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    340

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Cough, Dyspnea, IL-8

  • Treatment

    Other, SOC

  • Trial Participants

    292

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Cough, Fever, Dyspnea

  • Treatment

    TCM

  • Trial Participants

    40

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Cough, Fever, Dyspnea

  • Treatment

    SOC, TCM

  • Trial Participants

    40

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation

  • Treatment

    NA

  • Trial Participants

    4

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, PaO2-FiO2, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    294

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, Serious Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any)

  • Treatment

    TCZ

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, C-Reactive Protein, Natural Killer Cell Count, CD4, CD8

  • Treatment

    IFN, SOC

  • Trial Participants

    80

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Cough, Fever, Serious Adverse Events, C-Reactive Protein, Radiographic Findings

  • Treatment

    HCQ, Umifenovir

  • Trial Participants

    320

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, C-Reactive Protein, Radiographic Findings

  • Treatment

    DMARD, SOC

  • Trial Participants

    200

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    NA

  • Trial Participants

    40

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation

  • Treatment

    Other, SOC

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, TCM

  • Trial Participants

    200

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    80

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events

  • Treatment

    SOC, TCM

  • Trial Participants

    160

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Fever

  • Treatment

    SOC, TCM

  • Trial Participants

    160

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Dyspnea, C-Reactive Protein, PaO2-FiO2, SpO2, Radiographic Findings

  • Treatment

    mAb

  • Trial Participants

    27

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    FPV, SOC

  • Trial Participants

    210

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Other, SOC

  • Trial Participants

    40

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    300

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    750

Hubei
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Viral Load or Clearance, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    90

Hubei
  • COVID-19 status

    NA

  • Outcome

    Other Mild Symptoms

  • Treatment

    SOC, TCM

  • Trial Participants

    200

Hubei
  • COVID-19 status

    NA

  • Outcome

    Other Mild Symptoms

  • Treatment

    SOC, TCM

  • Trial Participants

    200

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    mAb, Other, SOC

  • Trial Participants

    120

Hubei
  • COVID-19 status

    Resolved

  • Outcome

    Antibodies, 6-Minute Walking Distance, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    Other, SOC

  • Trial Participants

    60

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Coagulation Test, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    160

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    42

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Viral Load or Clearance

  • Treatment

    Other, SOC

  • Trial Participants

    60

Hubei
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, C-Reactive Protein, Radiographic Findings

  • Treatment

    TCM

  • Trial Participants

    300

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Radiographic Findings

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Radiographic Findings

  • Treatment

    DRV/c + Other, LPV/r + Other, Other

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Respiratory Rate

  • Treatment

    LPV/r, SOC

  • Trial Participants

    328

Hubei
  • COVID-19 status

    Healthy

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever

  • Treatment

    Education + Monitoring + TCM, Psychological therapy

  • Trial Participants

    600

Hubei
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever

  • Treatment

    Education, Education + TCM

  • Trial Participants

    400

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, CD4, CD8

  • Treatment

    HCQ, SOC

  • Trial Participants

    300

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Cough, Fever, Other Mild Symptoms

  • Treatment

    Other

  • Trial Participants

    40

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Blood Pressure, Heart Rate, Surfactant Factor Protein, PaO2-FiO2, Respiratory Rate, Radiographic Findings

  • Treatment

    IFN, TCM

  • Trial Participants

    238

Hubei
  • COVID-19 status

    Resolved

  • Outcome

    Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life

  • Treatment

    Psychological therapy, SOC

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Cough, Fever, Adverse Events, 6-Minute Walking Distance, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, C-Reactive Protein, Procalcitonin, CD4, CD8, PaO2-FiO2

  • Treatment

    SOC, Stem cells

  • Trial Participants

    48

Hubei
  • COVID-19 status

    Resolved

  • Outcome

    Adverse Events, 6-Minute Walking Distance, Quality of Life

  • Treatment

    Exercise, SOC

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Suspected Or Healthy

  • Outcome

    Viral Load or Clearance, Fever, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Blood Pressure, Heart Rate, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    160

Hubei
  • COVID-19 status

    Resolved

  • Outcome

    Quality of Life, Depression, Anxiety

  • Treatment

    Psychological therapy, TCM, TCM + Psychological therapy

  • Trial Participants

    90

Hubei
  • COVID-19 status

    Resolved

  • Outcome

    Adverse Events, 6-Minute Walking Distance, Quality of Life

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    FPV, FPV + TCZ, TCZ

  • Trial Participants

    150

Hubei
  • COVID-19 status

    NA

  • Outcome

    Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, C-Reactive Protein, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), Procalcitonin, CD4, CD8, SpO2, Radiographic Findings

  • Treatment

    NA

  • Trial Participants

    30

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, Respiratory Rate, Radiographic Findings

  • Treatment

    NA

  • Trial Participants

    20

Hubei
  • COVID-19 status

    Confirmed

  • Outcome

    Radiographic Findings

  • Treatment

    NA

  • Trial Participants

    36

Hubei
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events

  • Treatment

    IFN, IFN + Other

  • Trial Participants

    2944

Huila
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    AZT, HCQ, LPV/r, SOC

  • Trial Participants

    1200

Hunan
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Pneumonia or ARDS, PaO2-FiO2, Respiratory Rate

  • Treatment

    Other

  • Trial Participants

    40

Hunan
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events

  • Treatment

    LPV/r, LPV/r + Other, Other

  • Trial Participants

    90

Hunan
  • COVID-19 status

    Confirmed

  • Outcome

    PaO2-FiO2, Respiratory Rate, Radiographic Findings

  • Treatment

    Antivirals, TCM + Antiviral

  • Trial Participants

    40

Hunan
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events, IL-2, IL-4, IL-6, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    900

Hunan
  • COVID-19 status

    Suspected

  • Outcome

    Anxiety

  • Treatment

    Psychological therapy, SOC

  • Trial Participants

    51

Hunan
  • COVID-19 status

    Healthy

  • Outcome

    Quality of Life

  • Treatment

    TCM

  • Trial Participants

    1000

Hunan
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    60

Hunan
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Viral Load or Clearance, Radiographic Findings

  • Treatment

    Stem cells

  • Trial Participants

    20

Hunan
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    NA

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Idaho
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)

  • Treatment

    HCQ, SOC

  • Trial Participants

    120

Idaho
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Idaho
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    174

Idaho
  • COVID-19 status

    Confirmed

  • Outcome

    Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    300

Idaho
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events

  • Treatment

    Razuprotafib, SOC

  • Trial Participants

    180

Idaho
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Illinois
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events

  • Treatment

    HCQ, HCQ + AZT, SOC

  • Trial Participants

    20

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    D-Dimer

  • Treatment

    Other, SOC

  • Trial Participants

    80

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2

  • Treatment

    mAb, SOC

  • Trial Participants

    384

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Anticoagulants, Antihypertensive, SOC

  • Trial Participants

    7000

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1230

Illinois
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Illinois
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin

  • Treatment

    SOC, SSRIs

  • Trial Participants

    152

Illinois
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    4000

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Fever, Ferritin, Lymphocyte Count, D-Dimer, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    30

Illinois
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    SOC, Triterpenes

  • Trial Participants

    440

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    66

Illinois
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    600

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH

  • Treatment

    Remdesivir, Remdesivir + mAb

  • Trial Participants

    200

Illinois
  • COVID-19 status

    NA

  • Outcome

    Mortality, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1300

Illinois
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospitalization

  • Treatment

    mAb, SOC

  • Trial Participants

    376

Illinois
  • COVID-19 status

    NA

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    10

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1344

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin

  • Treatment

    mAb, SOC

  • Trial Participants

    270

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + mAb

  • Trial Participants

    200

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    150

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein

  • Treatment

    SOC, TCZ

  • Trial Participants

    332

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    52

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, LDH

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    50

Illinois
  • COVID-19 status

    NA

  • Outcome

    Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2

  • Treatment

    Positioning

  • Trial Participants

    500

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    61

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Serious Adverse Events

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    600

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    500

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    SOC, Stem cells

  • Trial Participants

    30

Illinois
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Fever, Other Mild Symptoms, Adverse Events

  • Treatment

    DMARD

  • Trial Participants

    20

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Fever, Other Mild Symptoms, Adverse Events

  • Treatment

    HCQ

  • Trial Participants

    20

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Fever

  • Treatment

    Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone

  • Trial Participants

    525

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Non-invasive respiratory support, Positioning + Non-invasive respiratory support

  • Trial Participants

    346

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Illinois
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    TCZ

  • Trial Participants

    32

Incheon
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    76

Incheon
  • COVID-19 status

    Confirmed

  • Outcome

    Radiographic Findings

  • Treatment

    Monoclonal antibody

  • Trial Participants

    18

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2

  • Treatment

    mAb, SOC

  • Trial Participants

    384

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Indiana
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    66

Indiana
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospitalization

  • Treatment

    mAb, SOC

  • Trial Participants

    376

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    61

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    500

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Indiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Inner Mongol
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Urine Sample, Radiographic Findings

  • Treatment

    TCM

  • Trial Participants

    60

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    208

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Iowa
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    mAb, SOC

  • Trial Participants

    124

Iowa
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    600

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Iowa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    52

Islamabad
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Other Mild Symptoms, Treatment-emergent Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    200

Islamabad
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Islamabad
  • COVID-19 status

    Suspected

  • Outcome

    Mortality, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Lung Inflamation, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    ARBs, ARBs + Statins, NSAIDs, NSAIDs + ARBs, NSAIDs + ARBs + Statins, NSAIDs + Statins, Statins

  • Trial Participants

    10000

Islamabad
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Plasma based therapy, Plasma based therapy + TCZ + Remdesivir + Stem cells, SOC

  • Trial Participants

    600

Islamabad
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    100

Islamabad
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Islamabad
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    30

Islamabad
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    500

Islamabad
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Islamabad
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), C-Reactive Protein, D-Dimer

  • Treatment

    HCQ, HCQ + AZT, SOC

  • Trial Participants

    75

Istanbul
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    SOC, Stem cells

  • Trial Participants

    30

Istanbul
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    20

Istanbul
  • COVID-19 status

    Healthy

  • Outcome

    Mortality

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    50

Istanbul
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Other, SOC

  • Trial Participants

    200

Istanbul
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Istanbul
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    NA

  • Treatment

    Inhaled solution, SOC

  • Trial Participants

    60

Istanbul
  • COVID-19 status

    NA

  • Outcome

    Dyspnea, Other Mild Symptoms, Depression, Anxiety

  • Treatment

    Education, Non-invasive respiratory support

  • Trial Participants

    270

Istanbul
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Izmir
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    368

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Fever, Dyspnea, Blood Pressure, Heart Rate, SpO2, Respiratory Rate

  • Treatment

    AZT + Oseltamivir, Stem cells + AZT + Oseltamivir

  • Trial Participants

    40

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, C-Reactive Protein, D-Dimer, INR, Radiographic Findings

  • Treatment

    Plasma based therapy

  • Trial Participants

    10

Jakarta
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Treatment-emergent Adverse Events

  • Treatment

    SOC, Stem cells

  • Trial Participants

    9

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, D-Dimer, PaO2-FiO2

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    60

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Jakarta
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Jakarta
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    256

Jalisco
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Jalisco
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    66

Jalisco
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    410

Jalisco
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Patient Positioning

  • Treatment

    Positioning, SOC

  • Trial Participants

    200

Jerusalem
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    HCQ, SOC

  • Trial Participants

    1300

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    230

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    IFN, SOC

  • Trial Participants

    40

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    50

Jerusalem
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life

  • Treatment

    HCQ, HCQ + AZT

  • Trial Participants

    440

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Platelet Count, PaO2-FiO2

  • Treatment

    Cell-based therapeutic

  • Trial Participants

    24

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance

  • Treatment

    HCQ, SOC

  • Trial Participants

    5

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Jerusalem
  • COVID-19 status

    NA

  • Outcome

    Mortality, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1300

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    420

Jerusalem
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, HCQ + Other, SOC

  • Trial Participants

    250

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    40

Jerusalem
  • COVID-19 status

    NA

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Erythrocyte Sedimentation Rate, Procalcitonin, IgG, IgM or IgA, Antibodies, PaO2-FiO2

  • Treatment

    Non-invasive respiratory support

  • Trial Participants

    30

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    260

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, TCZ

  • Trial Participants

    500

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Other, SOC

  • Trial Participants

    40

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    SOC, Stem cells

  • Trial Participants

    140

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    100

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    270

Jerusalem
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13060

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, D-Dimer, Troponin

  • Treatment

    Anticoagulants

  • Trial Participants

    600

Jerusalem
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Dexamethasone, SOC

  • Trial Participants

    299

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance

  • Treatment

    Hygiene

  • Trial Participants

    70

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    460

Jerusalem
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Platelet Count, PaO2-FiO2

  • Treatment

    Apoptotic cells

  • Trial Participants

    5

Jiangsu
  • COVID-19 status

    Confirmed

  • Outcome

    Non-invasive Ventilation, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, ALT, PaO2-FiO2, Respiratory Rate

  • Treatment

    SOC, TCM

  • Trial Participants

    50

Jiangsu
  • COVID-19 status

    NA

  • Outcome

    Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers

  • Treatment

    SOC, Vaccine

  • Trial Participants

    500

Jiangsu
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Procalcitonin

  • Treatment

    SOC, TCM

  • Trial Participants

    100

Jiangsu
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Adverse Events, Weight, Height or BMI, Antibodies, Blood Pressure, ECG

  • Treatment

    mAb, SOC

  • Trial Participants

    456

Jiangsu
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Viral Load or Clearance, White Blood Cell Count, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    26

Jiangsu
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, C-Reactive Protein, IL-6, LDH, Respiratory Rate, Renal Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    90

Jiangsu
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    FPV

  • Trial Participants

    9

Jiangsu
  • COVID-19 status

    Healthy

  • Outcome

    Urine Sample, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    144

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, CD4, Respiratory Rate, Radiographic Findings

  • Treatment

    SOC, TCM

  • Trial Participants

    120

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Treatment-emergent Adverse Events

  • Treatment

    SOC, Stem cells + Natural Killer Cells

  • Trial Participants

    20

Jiangxi
  • COVID-19 status

    Resolved

  • Outcome

    Fever, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety, Distress

  • Treatment

    Exercise, Exercise + Respiratory support, Respiratory support

  • Trial Participants

    108

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever

  • Treatment

    SOC, TCM

  • Trial Participants

    72

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    LPV/r, LPV/r + TCM

  • Trial Participants

    80

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    100

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Stem cells

  • Trial Participants

    16

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Dyspnea, C-Reactive Protein, ALT, Bilirubin, Antibodies

  • Treatment

    Plasma based therapy

  • Trial Participants

    10

Jiangxi
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events, PaO2-FiO2, Respiratory Rate

  • Treatment

    DAA, IFN, TCM

  • Trial Participants

    50

Jilin
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    HCQ

  • Trial Participants

    10

Kaluga
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    mAb, SOC

  • Trial Participants

    204

Kampala
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    3000

Kampala
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

Kanagawa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Kanagawa
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Kanagawa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Kanagawa
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Kansas
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Kansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Kansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, Fever, Serious Adverse Events, IL-1, IL-8, Tumor Necrosis Factor (Any), SpO2, Distress

  • Treatment

    Other, SOC

  • Trial Participants

    36

Kansas
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    260

Kansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

Kansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other

  • Trial Participants

    2160

Kansas
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Bicarbonates

  • Treatment

    ARBs

  • Trial Participants

    34

Kansas
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Other, SOC

  • Trial Participants

    174

Kansas
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1000

Karnataka
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Organ Failure or Dysfunction (SOFA), Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Distress, Renal Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    24

Karnataka
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ + AZT, SOC

  • Trial Participants

    4000

Karnataka
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Karnataka
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge

  • Treatment

    Psychological therapy, SOC

  • Trial Participants

    40

Kathmandu
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    100

Kayseri
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other

  • Trial Participants

    60

Kayseri
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Kent
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    479

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    100

Kentucky
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    66

Kentucky
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Deep Vein Thrombosis or Pulmonary Embolism, Renal Outcome (Unspecified)

  • Treatment

    Other

  • Trial Participants

    366

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Kentucky
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    180

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia

  • Treatment

    Inhaled solution, SOC

  • Trial Participants

    144

Kentucky
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    Vaccine

  • Trial Participants

    120

Kentucky
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    260

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    61

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, D-Dimer

  • Treatment

    Plasma based therapy

  • Trial Participants

    100

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    mAb, SOC

  • Trial Participants

    300

Kentucky
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Serious Adverse Events

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    129

Kerman
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Stem cells

  • Trial Participants

    10

Kerman
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, SpO2, Respiratory Rate

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    80

Kermanshah
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    50

Kermanshah
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, C-Reactive Protein, IL-6, Lymphocyte Count, Erythrocyte Sedimentation Rate

  • Treatment

    Colchicine + Alternative therapy, SOC

  • Trial Participants

    200

Kermanshah
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    Other, SOC

  • Trial Participants

    50

Kermanshah
  • COVID-19 status

    Confirmed

  • Outcome

    Radiographic Findings

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    50

Khartoum
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, SpO2

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    3000

Khartoum
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance

  • Treatment

    Other

  • Trial Participants

    110

Khuzestan
  • COVID-19 status

    NA

  • Outcome

    Cough, Fever, Dyspnea

  • Treatment

    Other, SOC, Vitamins, Vitamins + Other

  • Trial Participants

    100

Khuzestan
  • COVID-19 status

    Confirmed

  • Outcome

    Platelet Count

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    88

Khuzestan
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge

  • Treatment

    HCQ + LPV/r, HCQ + LPV/r + Ivermectin

  • Trial Participants

    60

Khuzestan
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    DAA, SOC

  • Trial Participants

    1000

Kigali
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Mortality, Hospital Discharge, Pneumonia or ARDS, Distress

  • Treatment

    HCQ, HCQ + LPV/r, LPV/r, SOC

  • Trial Participants

    6400

Kirov
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Radiographic Findings

  • Treatment

    FPV, SOC

  • Trial Participants

    330

Kocaeli
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    13000

Konya
  • COVID-19 status

    Confirmed

  • Outcome

    Other Mild Symptoms, Quality of Life, Depression, Anxiety

  • Treatment

    Education, Exercise, Respiratory support

  • Trial Participants

    36

Krasnoyarsk
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Kuala Lumpur
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    230

Kuala Lumpur
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Kuala Lumpur
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance

  • Treatment

    Hygiene, SOC

  • Trial Participants

    20

Kuala Lumpur
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Kuala Lumpur
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Kuala Lumpur
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Corticosteroids, TCZ

  • Trial Participants

    310

Kuwait City
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Cyclosporin + Steroids

  • Trial Participants

    12

Kuwait City
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    300

Kuwait City
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Radiographic Findings, Hypoxia

  • Treatment

    FPV, SOC

  • Trial Participants

    780

Kyiv (Kiev)
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    190

Kyiv (Kiev)
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Pneumonia or ARDS, Cough, Fever, C-Reactive Protein, PaO2-FiO2

  • Treatment

    Antibiotics + AZT + Corticosteroids + Anticoagulants + Other, Stem cells + Antibiotics + AZT + Corticosteroids + Anticoagulants + Other

  • Trial Participants

    30

Kyiv (Kiev)
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    222

Kyiv (Kiev)
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Fever, Lymphocyte Count

  • Treatment

    Igs, SOC

  • Trial Participants

    76

Kyiv (Kiev)
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein

  • Treatment

    Other, SOC

  • Trial Participants

    100

Kyiv (Kiev)
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    60000

La Rioja
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Lacs
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein

  • Treatment

    LPV/r, LPV/r + Immunomodulators, LPV/r + Statins

  • Trial Participants

    294

Lancashire
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1450

Las Palmas
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Lecco
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Leeds
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    130

Leeds
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Leeds
  • COVID-19 status

    Healthy

  • Outcome

    IgG, IgM or IgA

  • Treatment

    SOC, Vitamins

  • Trial Participants

    4400

Leeds
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

Leeds
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Liaoning
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Depression, Anxiety, Distress

  • Treatment

    TCM

  • Trial Participants

    60

Liaoning
  • COVID-19 status

    Confirmed

  • Outcome

    Depression, Anxiety

  • Treatment

    Rehabilitation

  • Trial Participants

    160

Liaoning
  • COVID-19 status

    Confirmed

  • Outcome

    Viral Load or Clearance, Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate

  • Treatment

    DAA, SOC

  • Trial Participants

    20

Liaoning
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Quality of Life

  • Treatment

    TCM, TCM + Psychological therapy

  • Trial Participants

    60

Liaoning
  • COVID-19 status

    Confirmed

  • Outcome

    Pneumonia or ARDS, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    45

Liege
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    260

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    192

Lima
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Lima
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Lima
  • COVID-19 status

    NA

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    SOC, TCZ

  • Trial Participants

    379

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Lima
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    60000

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any)

  • Treatment

    mAb, SOC

  • Trial Participants

    573

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    177

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    10000

Lima
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    163

Lisbon
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Blood Pressure, Heart Rate, SpO2, Pregnancy or Birth Outcomes

  • Treatment

    Other, SOC

  • Trial Participants

    NA

Lisbon
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)

  • Treatment

    HCQ, LPV/r, Remdesivir

  • Trial Participants

    3100

Liverpool
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Liverpool
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Liverpool
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Liverpool
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    465

London
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, Serious Adverse Events, PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    24

London
  • COVID-19 status

    Suspected

  • Outcome

    Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    AZT, SOC

  • Trial Participants

    800

London
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    Radiation therapy

  • Trial Participants

    13

London
  • COVID-19 status

    Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    3000

London
  • COVID-19 status

    Healthy

  • Outcome

    Stool Sample, CD4

  • Treatment

    SOC, Vaccine

  • Trial Participants

    12390

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2, Respiratory Rate

  • Treatment

    FPV, HCQ + AZT + Zinc, SOC

  • Trial Participants

    450

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    230

London
  • COVID-19 status

    Suspected

  • Outcome

    Viral Load or Clearance

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    120

London
  • COVID-19 status

    Confirmed

  • Outcome

    Treatment-emergent Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    2500

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life

  • Treatment

    SOC, TCZ

  • Trial Participants

    450

London
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

London
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT

  • Treatment

    HCQ, LPV/r, SOC

  • Trial Participants

    6400

London
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Hygien, SOC

  • Trial Participants

    300

London
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Fibrinogen, PaO2-FiO2

  • Treatment

    Anticoagulants, SOC

  • Trial Participants

    36

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)

  • Treatment

    JAKi, mAb, SOC

  • Trial Participants

    375

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, CD4, CD8

  • Treatment

    Other, SOC

  • Trial Participants

    48

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

London
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Viral Load or Clearance, Other Mild Symptoms

  • Treatment

    HCQ, SOC

  • Trial Participants

    1000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

London
  • COVID-19 status

    Healthy

  • Outcome

    Serious Adverse Events

  • Treatment

    Vaccine

  • Trial Participants

    12330

London
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    300

London
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)

  • Treatment

    NA

  • Trial Participants

    15000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, Respiratory Rate, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    1800

London
  • COVID-19 status

    NA

  • Outcome

    Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Fibrinogen, PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    24

London
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    150

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    FPV, HCQ + AZT + Zinc, SOC

  • Trial Participants

    450

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Viral Load or Clearance

  • Treatment

    Hygiene, SOC

  • Trial Participants

    40

London
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    52

London
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, PaO2-FiO2

  • Treatment

    Inhaled solution, SOC

  • Trial Participants

    50

London
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, D-Dimer, Procalcitonin

  • Treatment

    Inhaled solution, SOC

  • Trial Participants

    40

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, Radiographic Findings

  • Treatment

    JAKi

  • Trial Participants

    NA

London
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, Troponin, Prothrombin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, Blood Pressure, Heart Rate, ECG, Respiratory Rate, Bicarbonates

  • Treatment

    Anticoagulants, Other, SOC

  • Trial Participants

    100

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any)

  • Treatment

    IFN, SOC

  • Trial Participants

    220

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, Neutrophils, D-Dimer, Triglycerides, LDH, PaO2-FiO2, SpO2, Respiratory Rate

  • Treatment

    mAb, Other

  • Trial Participants

    NA

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2

  • Treatment

    NSAIDs, SOC

  • Trial Participants

    230

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    Immunomodulators, JAKi, SOC

  • Trial Participants

    456

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH

  • Treatment

    Other, SOC

  • Trial Participants

    230

London
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    1090

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

London
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    222

London
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    60

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    JAKi, mAb, SOC

  • Trial Participants

    NA

London
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    SOC, SOC + Vaccine, Vaccine, Vaccine + Vaccine

  • Trial Participants

    9000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2

  • Treatment

    NSAIDs, SOC

  • Trial Participants

    NA

London
  • COVID-19 status

    Confirmed

  • Outcome

    C-Reactive Protein

  • Treatment

    Other, SOC

  • Trial Participants

    100

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

London
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Non-invasive Ventilation

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    400

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, SpO2, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    250

London
  • COVID-19 status

    Confirmed

  • Outcome

    Fever, Other Mild Symptoms, Serious Adverse Events, IgG, IgM or IgA, Antibodies

  • Treatment

    Vaccine

  • Trial Participants

    320

London
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    500

London
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Mortality, Hospital Discharge, Pneumonia or ARDS, Distress

  • Treatment

    HCQ, HCQ + LPV/r, LPV/r, SOC

  • Trial Participants

    6400

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, Surfactant Factor Protein, PaO2-FiO2

  • Treatment

    Other, SOC

  • Trial Participants

    20

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    Oseltamivir, Oseltamivir + Other

  • Trial Participants

    120

London
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events

  • Treatment

    Vaccine

  • Trial Participants

    10078

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin

  • Treatment

    DPP1 inhibitor, SOC

  • Trial Participants

    300

London
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    DPP1 inhibitor, SOC

  • Trial Participants

    300

London
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Other

  • Trial Participants

    2000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any)

  • Treatment

    Other, SOC

  • Trial Participants

    106

London
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    FPV, SOC

  • Trial Participants

    302

London
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Lymphocyte Count

  • Treatment

    Other, SOC

  • Trial Participants

    48

London
  • COVID-19 status

    Resolved

  • Outcome

    Adverse Events

  • Treatment

    Psychological therapy, SOC

  • Trial Participants

    26

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    300

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Viral Load or Clearance

  • Treatment

    FPV, LPV/r, LPV/r + FPV, SOC

  • Trial Participants

    240

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Serious Adverse Events, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    90

London
  • COVID-19 status

    Suspected

  • Outcome

    Visits or Returns to Emergency Department, Viral Load or Clearance, Fever, SpO2

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    478

London
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

London
  • COVID-19 status

    Healthy

  • Outcome

    Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    60

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, LDH, SpO2, Renal Outcome (Unspecified)

  • Treatment

    Other, Other + SGLT2, SOC

  • Trial Participants

    1407

London
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Clinical Improvement Score (Any)

  • Treatment

    IFN, SOC

  • Trial Participants

    820

London
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Hygiene

  • Trial Participants

    22

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, LDH

  • Treatment

    Antihypertensive, SOC

  • Trial Participants

    200

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Pneumonia or ARDS

  • Treatment

    AZT, SOC

  • Trial Participants

    800

London
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    NA

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    1034

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    389

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events

  • Treatment

    Hygiene, SOC

  • Trial Participants

    405

London
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Viral Load or Clearance, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Renal Outcome (Unspecified)

  • Treatment

    Anticoagulants, Other, SOC

  • Trial Participants

    NA

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    IL-1, IL-6

  • Treatment

    Anakinra, SOC

  • Trial Participants

    40

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, von Wildebrandt Factor, Troponin, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    NA

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Blood Gas, PaO2-FiO2, Respiratory Rate, Blood pH

  • Treatment

    Other, SOC

  • Trial Participants

    85

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Fever, Adverse Events, Bilirubin, Stool Sample

  • Treatment

    FPV, LPV/r, LPV/r + FPV, SOC

  • Trial Participants

    240

London
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Blood Pressure, Heart Rate, SpO2, Respiratory Rate

  • Treatment

    IFN, SOC

  • Trial Participants

    400

London
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers

  • Treatment

    Vaccine

  • Trial Participants

    1112

London
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2

  • Treatment

    mAb, SOC

  • Trial Participants

    270

London
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, Clinical Improvement Score (Any), Serious Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    150

London
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS

  • Treatment

    HCQ, SOC

  • Trial Participants

    40000

London
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    208

Louisiana
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events

  • Treatment

    HCQ, HCQ + AZT, SOC

  • Trial Participants

    20

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2

  • Treatment

    mAb, SOC

  • Trial Participants

    384

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, SOC

  • Trial Participants

    479

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Louisiana
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation

  • Treatment

    Other, SOC

  • Trial Participants

    200

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    1912

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Louisiana
  • COVID-19 status

    NA

  • Outcome

    Labor Absenteeism

  • Treatment

    HCQ, SOC

  • Trial Participants

    1700

Louisiana
  • COVID-19 status

    Healthy

  • Outcome

    Visits or Returns to Emergency Department, Antibodies

  • Treatment

    SOC, Vaccine

  • Trial Participants

    40051

Louisiana
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    500

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events

  • Treatment

    Other, SOC

  • Trial Participants

    80

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin

  • Treatment

    Remdesivir, Remdesivir + IFN

  • Trial Participants

    1038

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Serious Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1344

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB, SOC

  • Trial Participants

    2104

Louisiana
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    60

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin

  • Treatment

    mAb, SOC

  • Trial Participants

    270

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization

  • Treatment

    Antihypertensive, Antihypertensive + Nutrition, SOC

  • Trial Participants

    1080

Louisiana
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    HCQ, HCQ + AZT, SOC

  • Trial Participants

    600

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies

  • Treatment

    mAB

  • Trial Participants

    2970

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    702

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    66

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    38

Louisiana
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality

  • Treatment

    SOC, Vaccine

  • Trial Participants

    96

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    JAKi, SOC

  • Trial Participants

    500

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Louisiana
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    Plasma based therapy

  • Trial Participants

    NA

Louisiana
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, Vitamins

  • Trial Participants

    829

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any)

  • Treatment

    mAb, SOC

  • Trial Participants

    573

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    2000

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance

  • Treatment

    mAB, SOC

  • Trial Participants

    1200

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1062

Louisiana
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    1000

Louisiana
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation

  • Treatment

    NA

  • Trial Participants

    48

Louisiana
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    200

Lucerne
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Hemoglobin, D-Dimer, eGFR, Glucose, Renal Outcome (Unspecified)

  • Treatment

    mAb, SOC

  • Trial Participants

    116

Lusaka
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    30000

Luxembourg
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose

  • Treatment

    HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC

  • Trial Participants

    3100

Madhya Pradesh
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)

  • Treatment

    Other, SOC

  • Trial Participants

    40

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, Viral Load or Clearance

  • Treatment

    NA

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Neutrophils

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    120

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events

  • Treatment

    NA

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, CK-MB, Troponin, Fibrinogen, ALT, AST, Bilirubin, Glucose, LDH

  • Treatment

    TCZ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    NA

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Treatment-emergent Adverse Events, Ferritin, D-Dimer, LDH, PaO2-FiO2, Respiratory Rate

  • Treatment

    NA

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, ECG

  • Treatment

    Antivirals, SOC

  • Trial Participants

    200

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Non-invasive Ventilation, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), PaO2-FiO2

  • Treatment

    Anesthetic, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Ferritin, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Radiographic Findings, Hypoxemia, Renal Outcome (Unspecified)

  • Treatment

    Corticosteroids, Siltuximab

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    440

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Household Members with CoViD-19, Adverse Events, Hemoglobin, Weight, Height or BMI, Pregnancy or Birth Outcomes

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    230

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies

  • Treatment

    Remdesivir, Remdesivir + Other

  • Trial Participants

    10000

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Ferritin, IL-6, Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, LDH, CD4, Blood Pressure, Renal Outcome (Unspecified)

  • Treatment

    Cyclosporine, Darunavir, HCQ, IFN, LPV/r, Other, TCZ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, IgG, IgM or IgA, Radiographic Findings, Distress

  • Treatment

    Melatonin, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Ferritin, IL-1, IL-2, IL-6, IL-12, Tumor Necrosis Factor (Any), D-Dimer, Triglycerides, SpO2

  • Treatment

    Cyclosporine, TCZ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Cough, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings

  • Treatment

    SOC, TCZ + mAb

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, IL-6, D-Dimer, Renal Outcome (Unspecified)

  • Treatment

    AZT, HCQ, Sarilumab

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    30

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission

  • Treatment

    HCQ, SOC

  • Trial Participants

    800

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    Igs, Plasma based therapy

  • Trial Participants

    116

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    SOC, Vitamins

  • Trial Participants

    200

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Natural Killer Cells, Other

  • Trial Participants

    58

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Treatment-emergent Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    2500

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    NA

  • Trial Participants

    84

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Anti SARS-COV-2 Titers, Peak RC-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, ALT, AST, Albumin, Bilirubin, LDH, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings, Shock

  • Treatment

    HCQ, Imatinib, JAKi, LPV/r

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events

  • Treatment

    HCQ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life

  • Treatment

    SOC, TCZ

  • Trial Participants

    450

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Anticoagulants

  • Trial Participants

    164

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), D-Dimer, LDH

  • Treatment

    Colchicine, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    24

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Natural Killer Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, Electrolytes, INR, ALT, AST, Bilirubin, Glucose, LDH, IgG, IgM or IgA, CD4, CD8, Blood Urea Nitrogen, PaO2-FiO2, SpO2, Radiographic Findings

  • Treatment

    Stem cells

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, ALT, AST, LDH, Blood Urea Nitrogen, PaO2-FiO2, SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    Sarilumab

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events

  • Treatment

    mAb, SOC

  • Trial Participants

    800

Madrid
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance, Other Mild Symptoms

  • Treatment

    HCQ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Labor Absenteeism, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events, IL-2, IL-4, IL-6, IL-8, IL-12, Tumor Necrosis Factor (Any), Interferon (Any), MIP-1, Respiratory Rate

  • Treatment

    Vitamins

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Ferritin, IL-6, D-Dimer, LDH, Blood Pressure, PaO2-FiO2, SpO2, Radiographic Findings

  • Treatment

    Other

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, IL-1, IL-6, IL-8, IL-10, IL-12, Tumor Necrosis Factor (Any), PAI-1, Interferon (Any), White Blood Cell Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, ALT, AST, Bilirubin, Renal Outcome (Unspecified)

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    4891

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG

  • Treatment

    Other

  • Trial Participants

    46

Madrid
  • COVID-19 status

    NA

  • Outcome

    Adverse Events, Anti SARS-COV-2 Titers

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events, ACE

  • Treatment

    LPV/r + HCQ, Stem cells

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Hospitalization, Blood Gas, ECG, SpO2, Radiographic Findings

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Adverse Events

  • Treatment

    SOC, Stem cells

  • Trial Participants

    100

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    HCQ, LPV/r, Remdesivir, SOC

  • Trial Participants

    7000

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Adverse Events

  • Treatment

    Antivirals, SOC

  • Trial Participants

    1300

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, ECG

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH

  • Treatment

    Colchicine, SOC

  • Trial Participants

    6000

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    315

Madrid
  • COVID-19 status

    NA

  • Outcome

    NA

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    120

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6

  • Treatment

    HCQ, HCQ + NRTIs, NRTIs, SOC

  • Trial Participants

    4000

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers, White Blood Cell Count, Neutrophils, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, PaO2-FiO2, SpO2, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    mAb

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    420

Madrid
  • COVID-19 status

    NA

  • Outcome

    ICU Admission

  • Treatment

    Other

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Igs

  • Trial Participants

    100

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Ferritin, IL-1, IL-6, Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, LDH, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events

  • Treatment

    TCZ

  • Trial Participants

    500

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, SpO2

  • Treatment

    Anakinra, AZT, HCQ, LPV/r

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Ferritin, IL-6, D-Dimer, SpO2

  • Treatment

    Corticosteroids, HCQ + TCZ + LPV/r

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir

  • Trial Participants

    52

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Igs, SOC

  • Trial Participants

    100

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, SpO2

  • Treatment

    CCB, Other, SOC

  • Trial Participants

    804

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    100

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2, Respiratory Rate

  • Treatment

    Anticoagulants

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, IL-10, IL-12, IL-17, D-Dimer, Procalcitonin, PaO2-FiO2, SpO2, Radiographic Findings, Quality of Life

  • Treatment

    SOC, TCZ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), PaO2-FiO2

  • Treatment

    Anesthetic

  • Trial Participants

    50

Madrid
  • COVID-19 status

    Confirmed Or Healthy

  • Outcome

    Mortality, Viral Load or Clearance, Household Members with CoViD-19, Anti SARS-COV-2 Titers

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life

  • Treatment

    Other, SOC

  • Trial Participants

    120

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress

  • Treatment

    Other, SOC

  • Trial Participants

    100

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge

  • Treatment

    SOC, Vitamins

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance

  • Treatment

    SOC, Vitamins

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    Colchicine, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Viral Load or Clearance, Cough, Fever, Adverse Events, IgG, IgM or IgA

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Anakinra, SOC

  • Trial Participants

    180

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    mAb, Other, SOC

  • Trial Participants

    390

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)

  • Treatment

    JAKi, SOC

  • Trial Participants

    402

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies

  • Treatment

    Plasma based therapy, SOC

  • Trial Participants

    60

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    SpO2, Radiographic Findings

  • Treatment

    Radiation therapy

  • Trial Participants

    41

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings

  • Treatment

    Other, SOC

  • Trial Participants

    200

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Distress

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    SOC, Vaccine

  • Trial Participants

    315

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events

  • Treatment

    Remdesivir, SOC

  • Trial Participants

    1113

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Clinical Improvement Score (Any), Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    HCQ + Imatinib, HCQ + JAKi, HCQ + LPV/r

  • Trial Participants

    165

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality

  • Treatment

    SOC, Stem cells

  • Trial Participants

    106

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Shock

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance

  • Treatment

    Ivermectin, SOC

  • Trial Participants

    102

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events

  • Treatment

    HCQ, HCQ + Cyclosporine

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)

  • Treatment

    SGLT2, SOC

  • Trial Participants

    900

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    30

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    SOC, Stem cells

  • Trial Participants

    30

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality

  • Treatment

    SOC, Statins

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    NA

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Procalcitonin, PaO2-FiO2, SpO2, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    TCZ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    SpO2

  • Treatment

    Radiation therapy + Non-invasive respiratory support + LPV/r + HCQ + AZT + Other + Anticoagulants + Corticosteroids + TCZ

  • Trial Participants

    15

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, IL-12, IL-17, D-Dimer, Procalcitonin, PaO2-FiO2

  • Treatment

    SOC, TCZ

  • Trial Participants

    78

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, Cough, Fever, Dyspnea, Other Mild Symptoms

  • Treatment

    HCQ, SOC

  • Trial Participants

    1930

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events

  • Treatment

    Vaccine

  • Trial Participants

    10078

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge

  • Treatment

    HCQ + AZT, HCQ + LPV/r

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Invasive Mechanical Ventilation or ECMO

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    140

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Ferritin, IL-6, Erythrocyte Sedimentation Rate, Troponin, Fibrinogen

  • Treatment

    Colchicine, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), MIP-1, D-Dimer, Creatinine Phosphokinase, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, ALT, AST, Albumin, Bilirubin, Glucose, LDH, Renal Outcome (Unspecified)

  • Treatment

    SOC, Vitamins

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events

  • Treatment

    Monoclonal antibody, SOC

  • Trial Participants

    1360

Madrid
  • COVID-19 status

    NA

  • Outcome

    Viral Load or Clearance

  • Treatment

    Melatonin, SOC

  • Trial Participants

    450

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6

  • Treatment

    Immunomodulators, SOC

  • Trial Participants

    60

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified)

  • Treatment

    Sarilumab, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Corticosteroids, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Ferritin, D-Dimer, Radiographic Findings

  • Treatment

    Other

  • Trial Participants

    120

Madrid
  • COVID-19 status

    NA

  • Outcome

    Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Hemoglobin, Pregnancy or Birth Outcomes

  • Treatment

    HCQ, SOC

  • Trial Participants

    714

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    300

Madrid
  • COVID-19 status

    Healthy

  • Outcome

    Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    240

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Blood Gas

  • Treatment

    HCQ + AZT, Ivermectin

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Dyspnea, Ferritin, IL-6, Lymphocyte Count, D-Dimer, LDH, PaO2-FiO2, Respiratory Rate, Distress

  • Treatment

    Corticosteroids, TCZ

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Coagulation Test, LDH, PaO2-FiO2, SpO2, Radiographic Findings

  • Treatment

    SOC, Stem cells

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate

  • Treatment

    JAKi, SOC

  • Trial Participants

    1000

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose

  • Treatment

    Remdesivir, Remdesivir + JAKi

  • Trial Participants

    1034

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Ferritin, IL-6, D-Dimer, Procalcitonin, Antibodies

  • Treatment

    Igs, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    300

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Alternative therapy, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospital Discharge, C-Reactive Protein, Ferritin, IL-6, LDH

  • Treatment

    TCZ, TCZ + Vitamins

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Other, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, Coagulation Test, ALT, AST, Albumin, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)

  • Treatment

    SOC, TCZ + mAb

  • Trial Participants

    24

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils

  • Treatment

    Non-invasive respiratory support, SOC

  • Trial Participants

    208

Madrid
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    NA

  • Treatment

    Other, SOC

  • Trial Participants

    400

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    NA

  • Treatment

    Cyclosporine, SOC

  • Trial Participants

    120

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Hypoxemia

  • Treatment

    Corticosteroids, Siltuximab

  • Trial Participants

    200

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate

  • Treatment

    Other, SOC

  • Trial Participants

    380

Madrid
  • COVID-19 status

    NA

  • Outcome

    Adverse Events

  • Treatment

    SOC, Stem cells

  • Trial Participants

    26

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin

  • Treatment

    Remdesivir

  • Trial Participants

    52

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, LDH, PaO2-FiO2

  • Treatment

    Radiation therapy

  • Trial Participants

    41

Madrid
  • COVID-19 status

    Confirmed Or Suspected

  • Outcome

    ICU Admission, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events

  • Treatment

    JAKi + Statins, SOC

  • Trial Participants

    94

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2

  • Treatment

    Acalabrutinib, SOC

  • Trial Participants

    177

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO

  • Treatment

    Melatonin, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), Adverse Events

  • Treatment

    HCQ, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Ferritin, IL-6, IL-10, IL-12, Lymphocyte Count, D-Dimer, Troponin

  • Treatment

    Other, SOC

  • Trial Participants

    NA

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2

  • Treatment

    Other, SOC

  • Trial Participants

    1034

Madrid
  • COVID-19 status

    Confirmed

  • Outcome

    Mortality, Clinical Improvement Score (Any), Treatment-emergent Adverse Events, ECG

  • Treatment

    SOC, Trimodulin

  • Trial Participants

    164

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Radiographic Findings

  • Treatment

    HCQ + AZT or LPV/r + IFN, Plasma based therapy

  • Trial Participants

    72

Madrid
  • COVID-19 status

    NA

  • Outcome

    Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanica